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Prostate cancer incidence and mortality have been decreasing in recent years, but 
it remains the most commonly diagnosed cancer among men. Racial disparities exist in 
prostate cancer with African Americans (AAs) having notably higher rates of incidence 
and mortality, lower survival rates, and are more likely to be diagnosed with a higher-
grade cancer compared to European Americans (EAs). Genome-wide association studies 
have revealed several single nucleotide polymorphisms (SNPs) within the vitamin D-
related GC gene that may be associated with prostate cancer aggressiveness. In addition 
to SNPs, previous research has suggested that low levels of 25-hydroxyvitamin D 
(25(OH)D) may be related to prostate cancer risk and aggressiveness, though studies are 
inconsistent. Low levels of 25(OH)D are more common among AAs than other 
racial/ethnic groups, thus vitamin D and related genes may play a role in prostate cancer 
racial disparities. The current study utilized data from the North Carolina-Louisiana 
Prostate Cancer Project (PCaP) to assess the relationship between 28 GC SNPs, the 
combined genotypes for rs7041 and rs4588, and a polygenic risk score with low levels of 
25(OH)D and aggressive prostate cancer in AAs (n=524) and EAs (n=657). None of the 
combined genotype categories were significantly associated with aggressive prostate 
cancer among AAs, and only one significantly decreased risk among EAs (Gc1s-1s, OR: 
0.38, 95% CI: 0.17, 0.85). Significant associations with aggressive prostate cancer were 
observed in the additive and dominant genetic models, but not the recessive model. Two 
SNPs in AAs (rs222054 and rs16847028) and one SNP in EAs (rs6817912) significantly 
decreased the risk of high aggressive prostate cancer. Four SNPs among AAs (rs4588, 
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rs2282679, rs3755967 and rs17467825) and eight SNPs among EAs (rs4588, rs7041, 
rs222040, rs705119, rs705120, rs2282679, rs3755967 and rs17467825) significantly 
increased the risk of having low levels of 25(OH)D. A polygenic risk score of two SNPs 
(rs4588-CC and rs222054-CC) reflecting higher levels of 25(OH)D significantly 
decreased the risk of high aggressive prostate cancer among AAs. There was no evidence 
of interaction between the polygenic risk score and 25(OH)D on the association with 
aggressive prostate cancer. This study identified two SNPs GCrs4588 and GCrs222054 
that appear to affect levels of vitamin D and prostate cancer aggressiveness among AAs. 
Future studies should further examine the relationship of these SNPs with prostate cancer 
and 25(OH)D in AAs. 
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Prostate Cancer Background 
 Prostate cancer ranked third among the most common types of cancers among all 
Americans accounting for 9.5% of all new cancer cases and 4.8% of all cancer deaths in 
2018.1 In 2019, this continues to be true with prostate cancer among men responsible for 
20% of all new cases (174,650 new cases) and 10% of all cancer deaths (31,620 deaths).2 
A 7% reduction in incidence occurred annually among men during 2011 through 2015; 
this is believed to be a result of the recommendation given by the United States (US) 
Preventive Services Task Force against prostate-specific antigen (PSA) blood testing for 
all men in 2008.2 This recommendation was revised in 2017, encouraging testing for men 
between the ages of 50 and 69.2 According to the Surveillance, Epidemiology, and End 
Results (SEER) data from 2013-2015, the lifetime probability of developing invasive 
prostate cancer was 11.2% (1 in 9) with a 98% 5-year survival, and prostate cancer 
accounts for an estimated 10% of cancer deaths.1,2 Although incidence and mortality has 
decreased over the years, prostate cancer remains as the most commonly diagnosed 
cancer among males accounting for 1 in every 5 new diagnoses and the second leading 
cause of cancer deaths in both 2018 and 2019.2,3   
Racial Disparities 
Incidence, Mortality, and Survival 
Although incidence and mortality rates for prostate cancer have been steadily 
decreasing, the rates among African Americans (AA) are notably higher than those 
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among European Americans (EA). Based on cases from 2011-2015, incidence rates are 
higher for AAs (178.3 per 100,000 men) versus EAs (105.7 per 100,000 men) per year, 
making the risk of developing prostate cancer among AAs 1.68 times higher than the risk 
among EAs, after adjusting for age.1 The conclusion is similar for mortality, the risk of 
dying from prostate cancer among AAs (39.9 per 100,000 men) is 2.19 times the risk 
among EAs (18.2 per 100,000), after adjusting for age.1 Survival rates are far worse 
among AA compared to EA, which is believed to be related to tumor stage at diagnosis. 
In a follow-up analysis done by Jones et al., survival rates were significantly lower 
among AA compared to EAs (hazard ratio, 1.53; 95% CI, 1.13-2.08) after adjusting for 
age at diagnosis. High stage and tumor grade explained some of these disparities such 
that when adjusted for, survival slightly improved for AA compared to EAs (hazards 
ratio, 1.26; 95% CI, 0.92-1.73).4   
Stage and Grade at Diagnosis and Progression 
 The Gleason grading system is an important tool in determining the prognosis and 
treatment in prostate cancer. In 2004, the use of the Gleason grading system in the 
categorization of prostate cancer was endorsed by the World Health Organization 
(WHO).5 The grading scale ranges from 1-5, with numbers being assigned to the two 
regions that make up most of the tumor. The summation of these two numbers creates the 
number known as the Gleason sum; the first number represents the grade that makes up 
the larger portion of the tumor. The grade number is dependent on how the appearance of 
cells in cancerous tissue compares to cells in normal prostate cancer tissue. A score of 1 
is considered to describe cells that are roughly uniform and similar in appearance to 
normal cells, while a score of 5 represents complete abnormal growth of cells within the 
tissue.5,6 According to the 2005 International Society of Urological Pathology (ISUP) 
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consensus, a Gleason sum = 2 (1+1) is considered to describe adenosis of the prostate 
gland and therefore should no longer be diagnosed, and sums of 3 and 4 should be rare.5 
The lowest Gleason sum is commonly 6 and categorized as a low-grade tumor, while a 
Gleason sum between 8-10 is categorized as a high-grade tumor.6 
Based on the data from SEER 18 2008-2014, 90% of cases were diagnosed at 
early stages, localized (78%) and regional (12%), while 5% and 4% were diagnosed at a 
late stage (distant) and unknown (un-staged), respectively.1 The 5-year survival rates 
were 100%, 30% and 80% for early (localized and regional), late (distant) and unknown 
stages, respectively.1,2 Thus, although incidence is higher for low grade/early stage 
compared to high grade/late stage, the survival rate is much lower for those with high 
grade/early stage prostate cancer.  
Disparities exist between AA and EA in tumor stage, grade, and progression. 
According to SEER data for 2008-2014, higher proportions of localized and distant 
stages in prostate cancer were more likely to be found among AAs versus EAs.2 In a 
study by Freeman et al., AA tended to present with more advanced/distant stages (30%) 
and histological grade (33%) compared to EA (12% and 19%).7 In another study, the 
odds of a non-localized diagnosis were significantly greater among AAs compared to 
EAs (unadjusted OR = 2.02; 95% CI, 1.21-3.38) with 60% and 43% of non-localized 
prostate cancer diagnosis among AA and EAs in the study population, respectively.4 
Progression and transformation from latent to aggressive prostate cancer occurred more 
rapidly among AAs compared to EAs, with advanced or metastatic stages occurring at a 




Age, race, and family history are the three definitive risk factors for prostate 
cancer. Several other potential risk factors may explain the racial disparities found in the 
diagnosis, treatment, and survival of prostate cancer between AAs and EAs.  
 As discussed previously, AA are more likely to be diagnosed with more 
aggressive forms of prostate cancer. Healthcare access, insurance, socioeconomic status 
(SES), and screening procedures such as digital rectal exams (DRE) and prostate specific 
antigen (PSA) testing are variables of interest in explaining the disparities found in 
aggressiveness of disease at diagnosis between AA and EA. In a study assessing race-
stage associations between AA and EAs, understanding one’s insurance coverage, SES 
factors, and medical care factors reduced the odds of a higher stage at diagnosis for AA 
compared to EA (race-stage OR) by 22%, 20%, and 11% respectively. Screening history 
and clinical factors reduced the odds by 11.2% and 12.8%, respectively. The race-stage 
odds ratio (OR=1.83; 95% CI:1.06-3.15) reduced by 74% in the final multivariable model 
(OR=1.21; 95 % CI:0.64-2.30) that included DRE, histological grade, education, and 
understanding one’s insurance coverage.4 
 Racial disparities exist in treatments received which in turn have an effect on 
survival and mortality in prostate cancer. In a study by Mahal et al., a significant 
association was found between race and insurance status in receiving definitive treatment 
among men with high-risk prostate cancer. AA were not only more likely to be uninsured 
but also had the highest rate (27%) of not receiving definitive treatment among men with 
high-risk prostate cancer. The odds of receiving definitive treatment for insured men 
compared to uninsured men was greater among AA (AOR = 2.23; 95% CI: 1.72–2.88) 
versus EA  (AOR = 1.47; 95% CI: 1.15–1.89), after adjusting for sociodemographic and 
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cancer-specific factors.9 Healthcare access-related factors seemingly play an essential 
role in not only treatment but also in survival.  In a study by Krimphove at el., survival 
among AA men was significantly worse compared to EA men (HR = 1.27; 95% CI: 
1.20–1.34). After access to care was taken into consideration, there was no longer a 
significant difference in survival between the races (HR = 1.04; 95% CI: 0.97–1.12). 
When access to care and tumor characteristic were the same for both races, AA men were 
slightly more likely to survive compared to EA men (HR = 0.93; 95% CI: 0.86–1.01). It 
is estimated that access to care and tumor-related factors accounted for 84% and 4%, 
respectively, of the excess risk of death due to prostate cancer among AA men.10 
Genetics 
 Genome-wide association studies (GWAS) have revealed several genetic variants 
which are believed to be associated with prostate cancer, but GWAS is limited in its 
ability to be generalizable to populations that are not of European or Asian descent. The 
US is only responsible for 19% of GWAS publications, with AA making up a small 
percentage of the study populations (3%) compared to EAs (79%).11 Differences found in 
prostate cancer pathogenesis and progression influenced both diagnosis and treatment 
distinctly among AAs compared to EAs.12 These differences have been examined in 
replications studies on an AA study population using known genetic risk variants from 
GWAS. These variants not only contributed to risk but also better captured the pattern of 
risk of prostate cancer in AAs.13,14 The underrepresentation of AAs in genetic studies and 
some differences in the distribution of genetic polymorphisms between populations of 




Vitamin D    
 Research has suggested that vitamin D status may be related to prostate cancer 
risk and aggressiveness. Determination of vitamin D status occurs through the 
measurement of circulating plasma levels of 25-hydroxyvitamin D (25(OH)D). Levels of 
25(OH)D have been shown to differ by race, with higher frequency of vitamin D 
insufficiency or deficiency among AAs compared to other racial/ethnic groups. 
Deficiency can be a result of many factors such as low dietary intake and decreased 
endogenous synthesis with ultraviolet exposure. Individuals with darker skin 
pigmentation tend to have lower levels of vitamin D due to blocking of vitamin D 
synthesis by melanin. In a study by Egal et al., mean levels of 25(OH)D were lower in 
AAs than EAs with 28% of the total study population defined as hypovitaminosis D. A 
larger proportion of AAs (45%) than EAs (11%) had hypovitaminosis D.15 It has been 
hypothesized that the racial disparity in vitamin D status may be contributing to the 
disparity of prostate cancer observed in AA. In a study by Shui et al., a significant inverse 
association was present between plasma 25(OH)D levels and lethal prostate cancer (OR = 
0.43; 95% CI: 0.24-0.76).16 Among men with cancer, the odds of having a higher clinical 
stage increased with lower levels of 25(OH)D (OR: 4.22; 95% CI: 1.52 – 11.74).17 When 
comparing clinical stages, the odds of a prostate cancer diagnosis on biopsy increased 
with low levels of 25(OH)D in AA (OR = 2.43; 95% CI: 1.20 - 4.94).17 In contrast, AA 
men with high aggressive prostate cancer actually had higher concentrations of 25(OH)D 
compared to AA men with low aggressive disease in the North Carolina-Louisiana 
Prostate Cancer Project (PCaP).18 Thus, the relationship between 25(OH)D and prostate 
cancer disparities is complex and may be mediated by genetic susceptibility factors.   
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Proposal and Specific Aims  
 The purpose of this study was to examine the association between single 
nucleotide polymorphisms (SNPs) in a vitamin D-related gene and aggressive prostate 
cancer among AAs and EAs in a large population-based case-only study. Data on SNPs 
and prostate cancer aggressiveness were obtained from PCaP. High aggressive prostate 
cancer was classified based on clinical stage, PSA and Gleason score. My specific aims 
are as follows: 
1) To describe the mean and standard deviation of 25(OH)D by combined 
genotypes of the vitamin D binding protein gene (GC) for the commonly studied 
rs7041 and rs4588 SNPs in AA and EA men diagnosed with prostate cancer; 
2) To assess the relationship between the combined genotypes, 28 GC SNPs with 
both 25(OH)D and aggressive prostate cancer by race, and  
3) To create a polygenic risk score in order to examine its association with both 
25(OH)D and aggressive prostate cancer and its interaction with 25(OH)D by 
race. 
Significance of Research 
 Prostate cancer continues to be the most commonly diagnosed cancer and second 
leading cause of cancer death among men in the US with AAs having the highest rate of 
incidence.2,3 Although survival rates are highest for prostate cancer (98%) compared to 
other types of cancer, survival rates have been shown to be worse among AAs.2,10 AAs 
are experiencing the highest mortality rates compared to all races combined (39.8 vs 19.2 
per 100,000, respectively) and rates are more than doubled when comparing AAs to EAs 
(39.8 vs 18.1 per 100,000).2  According to the Detroit SEER, advanced and metastatic 
stages occurred at a ratio of 4:1 and tumor progression and transformation occurred more 
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rapidly when comparing AAs to EAs.8 Several studies have inferred that prostate cancer 
risk can be influenced by both vitamin D levels and GC SNPs rs7041 and rs4588.19,20 
This becomes problematic for the male AA population, who were more likely to possess 
alleles associated with decreasing levels of vitamin D and to be categorized as 
hypovitaminosis D compared to the male EA population.15,21 
The lack of AAs in GWAS study populations (3%) speaks to the need for more 
research studies to be conducted within this population.11 This study is focusing on the 
genetic determinants of aggressive prostate cancer among AA males. Results from this 
study can contribute to the current literature on the association between aggressive 
prostate cancer and the interaction of GC SNPs rs7041 and rs4588, and 25(OH)D levels 
for future use towards prevention interventions and personalized treatments. 
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CHAPTER 2 
BACKGROUND & LITERATURE REVIEW
 
Vitamin D Pathway  
 Studies have suggested that vitamin D can potentially play an important role in 
reducing the risk of cancer and improving prognosis. However, a recent randomized 
controlled trial found no evidence for cancer prevention among older individuals 
randomized to receive 2000 IU vitamin D per day during a median follow-up of 5.3 
years.22 Effects of vitamin D supplementation are likely to be dependent on baseline 
vitamin D status, as well as genetic variation in genes involved in vitamin D metabolism, 
which is a major focus of the proposed study. 
Synthesis of vitamin D occurs in multiple steps, beginning in the skin through 
ultraviolet exposure from the sun or absorption from diet and supplements. This process 
converts vitamin D into vitamin D3, which binds to the vitamin D-binding protein (DBP) 
and travels to the liver.23,24 In the liver, D3 is converted into 25-hydroxyvitamin D, 
25(OH)D3 (referred to as 25(OH)D) via 25-hydroxylase enzymes. The two protein-coding 
genes responsible for 25-hydroxylation are CYP2R1 and CYP27A1. 25(OH)D is the main 
circulating form and most commonly used vitamin D metabolite to measure vitamin D 
status.23,25 25(OH)D binds to DBP and transports to the kidney where it hydrolyzes into 
1,25-dihydroxyvitamin D, 1,25(OH)2D3 (referred to as 1,25(OH)2D or calcitriol), by 1a-
hydroxylases; CYP27B1 is the gene responsible for 1a-hydroxylation.25 As described in 
Chapter 1, AAs have lower circulating concentrations of 25(OH)D compared to EAs, 
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however, most studies have found 1,25(OH)2D concentrations to be similar between AAs 
and EAs, likely due to homeostatic regulation.  
DBP binds to both forms of vitamin D metabolites and circulates them to target 
tissues. Usually bound, 25(OH)D is transported back to the liver or circulated through the 
blood, while bound 1,25(OH)2D is transported to target sites such the kidney, intestine 
and bone.25 1,25(OH)2D is the hormonal metabolite of vitamin D and binds to the nuclear 
vitamin D receptor (VDR) in target cells where it regulates the expression of about 200-
300 genes.24,25 1,25(OH)2D is self-regulated and degraded by the 24-hydroxylase enzyme 
and corresponding CYP24A1 gene.24  Thus, there are at least six possible genes involved 
in the overall vitamin D pathway which have been examined in epidemiologic studies: 
25-hydroxylase (CYP2R1 and CYP27A1 genes), 1a-hydroxylase (CYP27B1 gene), 24-
hydroxylase (CYP24A1 gene), VDR (VDR gene), and DBP (GC gene). Studies show that 
SNPs within some of these genes may affect circulating vitamin D levels and contribute 
to the risk of prostate cancer.  
Vitamin D Related Genes  
Prostate Cancer  
 The most studied vitamin D gene is VDR which has multiple common SNPs that 
have been investigated in relation to cancer risk. For three VDR SNPs, prostate cancer 
risk increased (FokI- rs2228570) and even doubled (rs2107301 and rs2238135) among 
men who possessed the rare allele compared to those who possessed the common allele, 
with the highest risk among men who were homozygous for the rare allele.26,27 Among 
men with prostate cancer, VDR SNPs were associated with increased risk for tumor 
progression (rs6823 and rs2071358) and risk of death (rs3782905, rs7299460, and 
rs1168314).28 Haplotypes of VDR associated with prostate cancer showed risk increasing 
11 
as the number of risk alleles increased.29 Other haplotypes demonstrated a significant 
association with both aggressive (p=0.02) and lethal prostate cancer (p= 0.01).16,30 Some 
studies have shown that haplotype frequencies may be significantly different among AAs 
with prostate cancer compared to AAs without cancer (p = 0.059).26 In addition to the 
risk of prostate cancer, VDR SNPs were also associated with high PSA levels (p<0.05) 
and Gleason scores (p<0.05).29  
 Other vitamin D pathway genes and haplotypes possibly associated with prostate 
cancer include CYP2R1, CYP27A1, CYP27B1, CYP24A1, and GC. SNPs in CYP24A1, 
CYP27B1, and VDR showed a significant increase in the risk of tumor progression (VDR: 
rs6823 and rs2071358, CYP24A1: rs927650 and rs2762939) and death (VDR: rs3782905, 
rs7299460, and rs11168314, CYP27B1: rs3782130 and CYP24A1: rs3787557, 
rs4809960, rs2296241, rs2585428, and rs6022999) among men diagnosed with prostate 
cancer.28 Pathway analysis showed a significant association between lethal prostate 
cancer and a set of SNPs (p = .008) that included the following genes: CYP27A1, 
CYP2R1, CYP27B1, GC, CYP24A1, RXRA, and VDR, but when genes were examined 
individually, only individual sets of CYP27A1 were associated with lethal prostate cancer 
(p = .02).16 
 Although some studies exist showing strong evidence of associations between 
vitamin D-related gene SNPs and prostate cancer, not all studies are supportive.31,32 Small 
sample sizes along with low frequency of SNPs may have reduced power to observe any 





GC Gene  
SNPs (rs7041and rs4588) 
 The GC gene may be particularly important in determining vitamin D metabolite 
concentrations given that it encodes the DBP which is responsible for vitamin D 
transport. A few studies have examined the relationship and interactions between GC 
SNPs (rs7041 and 4588), prostate cancer, 25(OH)D levels and DBP levels (Table 2.1). 
Significant associations were observed between GC SNPs (rs7041-T and rs4588-A) 
related to low levels of 25(OH)D and increased prostate cancer risk (rs4588: OR 1.20, 
95% CI 1.01-1.41 ; rs7041: OR 1.19, 95 % CI 1.02-1.38).19,20 When examining the 
genotypes within rs7041 and rs4588, lower levels of  25(OH)D were associated with the 
‘AA’ genotype in rs7041, ‘TT’ genotype in rs4588 and ‘AT/AT + AG/AT’ haplotypes.33 
Genotypic variations of these two SNPs have been linked to differences in 25(OH)D 
levels between AAs and EAs. Both SNPs were found to have significant associations 
with 25(OH)D among AAs (p < 0.01).34 In a study by Powe et al., AAs are more likely to 
have the “T” allele at rs7041 (p<0.001), which is also the allele associated with 
decreasing levels of 25(OH)D in AAs. In the same study, SNPs (rs7041 and rs4588) and 
race explained 9.9% and 7.3%, respectively, of the variation present in 25(OH)D levels.21 
Other studies have combined these two SNPs to create combined genotypes and found 
that certain genotypes were significantly associated with colorectal cancer in males or 
lung cancer.35 
Vitamin D Binding Protein Levels 
 Different GC genotypes are associated with levels of DBP. 25(OH)D binds to 
DBP to be transported to target cells to freely circulate or for conversion into the 
hormonal form of vitamin D. According to the ‘free hormone hypothesis,’ biological 
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activity is dependent on the unbound form of vitamin D metabolites, also known as ‘free’ 
or ‘bioavailable’ 25(OH)D, versus its protein-bound form.36 For this reason, studies have 
examined possible associations and interactions occurring between DBP levels, levels of 
circulating 25(OH)D, GC SNPs and prostate cancer risk. In a study by Powe et al., 
differences in DBP levels were observed between AAs and EAs, with lower mean levels 
in AAs.21 The ‘T’ allele in rs7041 and the ‘A’ allele in rs4588 were associated with 
decreasing levels of DBP in both races. AAs were more likely to have the ‘T’ allele in 
rs7041 (p< 0.001) and least likely to have the ‘A’ allele in rs4588 (p<0.001).21  
Research has suggested that risk of cancer decreases in the presence of high levels 
of DBP, but some studies have proposed the association was a result of the interaction 
occurring between DBP and 25(OH)D.37–39  Among men with high levels of DBP, low 
levels of 25(OH)D were associated with decreased risk for overall prostate cancer but 
increased risk of advanced prostate cancer.40,41 
Vitamin D Levels and Genetic Interactions 
 Some vitamin D-related genes and SNPs are associated with different 
corresponding levels of 25(OH)D, while other gene SNPs appear to be interacting with 
25(OH)D levels to affect prostate cancer risk. Risk alleles for GC and CYP27B1 tag 
SNPs, in particular, have been associated with levels of 25(OH)D. Three tag SNPs in the 
GC gene (rs12512631, rs2282679 and rs1155563) were found to be significantly 
associated with 25(OH)D levels (p=0.0004), but there were two SNPs in GC (rs2298849 
and rs2282679) and one in CY27PB1 (rs10877012) that resulted in an association only 
among AA individuals.19,42   
Several studies have found evidence of interactions occurring between vitamin-D 
related SNPs and levels of 25(OH)D in association with prostate cancer risk. Significant 
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associations were observed between one VDR SNP (rs11574143) and risk of prostate 
cancer only among men with low levels of 25(OH)D (p=0.0007).19 Risk of total and 
aggressive prostate cancer increased among men with low levels of 25(OH)D who 
possessed the less functional allele for VDR SNP FokI.43 In contrast, among those who 
carried the less functional allele for VDR FokI but were categorized with high levels of 
25(OH)D, risk decreased by 60-70% for total and aggressive prostate cancer.43 Other 
observed vitamin-D related gene associations revealed SNPs may have a different effect 
on aggressive and non-aggressive disease. For example, CYP24A1 rs6013897 was 
associated with low levels of 25(OH)D and a decreased risk of aggressive prostate cancer 
but an increased risk for non-aggressive disease (p=0.0002).44 Different levels of 
25(OH)D can also create different associations for a SNP and disease. Associations 
between five SNPs in GC (rs1155563) and CYP2R1 (rs2060793, rs12794714, 
rs1562902, and rs11023374) and fatal prostate cancer risk were dependent upon the 
amount of circulating 25(OH)D present.31  
Another method used to observe associations between SNPs, 25(OH)D and 
prostate cancer is the use of genetic risk scores. Studies have created genetic risk scores 
in order to find new associations or strengthen existing ones by considering more than 
one SNP or gene in the model. In a study by Signorello et al., a risk score was created 
using the sum of risk alleles in three SNPs (GC:rs2298849, rs2282679 and 
CYP27B1:rs10877012) which ranged between 1 and 5 among AA. Among individuals 
with a score of 5, the risk for vitamin D insufficiency was six times greater compared to 
those with a score of 1 (p=0.01).42 Another study coded SNPs in four genes (GC, 
CYP241, CYP2R1, and DHCR7) according to the number of alleles associated with low 
25(OH)D which were then combined in order to create a polygenic risk score ranging 
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from 0 to 8. Among men with a score of 6-8 reflecting low concentrations of 25(OH)D, 
the risk of aggressive prostate cancer decreased compared to those with 0-1 (OR for 6–8 
vs. 0–1 alleles, 0.66; 95% CI, 0.44–0.98).44  
These studies underscore the importance of considering interactions between 
vitamin D-related SNPs and levels of 25(OH)D in relation to the risk of prostate cancer 
aggressiveness. Levels of vitamin D and respective SNPs may infer main effects 
individually with prostate cancer risk, but as the studies above demonstrated, interaction 
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The study utilizes data from the North Carolina-Louisiana Prostate Cancer Project 
(PCaP), a population-based case-only study examining determinants of racial differences 
in prostate cancer aggressiveness. This study used data from an ancillary project titled 
“Vitamin D and Related Genes, Race, and Prostate Cancer Aggressiveness” to estimate 
associations between vitamin-D related SNPs and prostate cancer aggressiveness.  
2. Sample Size 
A subset of the PCaP population consisting of 1200 research subjects with data on 
vitamin D status and related genes were utilized. All research subjects diagnosed with 
high aggressive prostate cancer in PCaP (n = 302) and 112 research subjects diagnosed 
with Gleason score = 4+3 (all other intermediate aggressive cancer research subjects 
were excluded) were included and comprised the high aggressive cases. A random subset 
(n = 786) of research subjects diagnosed with low aggressive cancer were included as the 
comparison group. A random subset was selected because there were many more low- 
aggressive cancer cases than needed for analyses. The selection of research subjects for 
this ancillary study was completed prior to any 25(OH)D3 lab measurements or data 
analyses.18 
3. PCaP Methods 
3.1 Study Population  





histologically confirmed adenocarcinoma of the prostate between July 2004 and 
July2009.”18 As explained in the paper by Schroeder et al., participants were recruited 
from 42 counties in North Carolina and 13 parishes surrounding New Orleans in 
Louisiana. Enrollment was broken down into two phases for Louisiana, one each for pre- 
and post- Hurricane Katrina. The first phase lasted from July 2004 through August 2009, 
the remainder of the time was considered the second phase which included 8 additional 
parishes. Participants needed to “complete the study interview in English, not live in an 
institution (nursing home), not cognitively impaired or in a severely debilitated physical 
state, and not under the influence of alcohol, severely medicated, or apparently psychotic 
at the time of the interview. Eligible men also must self-identify as at least part African 
American/Black or Caucasian American/ White in response to the open-ended interview 
question ‘‘What is your race?’’ Participants who indicate more than one group are asked 
if one best describes them; if not, multiple groups are recorded.”45 
3.2 Rapid Case Ascertainment Eligible 
“Eligible North Carolina patients [were] identified by the Rapid Case 
Ascertainment Core Facility, a collaborative effort of the UNC-Lineberger 
Comprehensive Cancer Center and the North Carolina Central Cancer Registry 
(NCCCR). North Carolina state law mandates regular reporting of all newly diagnosed 
cancers (excluding non-melanoma skin cancers), and the NCCCR is authorized to release 
contact and eligibility information to PCaP by the North Carolina Advisory Committee 
on Cancer Coordination and Control. In Louisiana, eligible patients [were] identified by 
the Louisiana Tumor Registry (LTR) in the School of Public Health at LSUHSC. LTR 
operations are mandated by Louisiana law, which directs all hospitals, pathology 





provide LTR staff with access to this information. Case ascertainment field 
representatives abstract[ed] pathology reports, review[ed] information used to screen 
eligibility and ensure[d] that ascertainment in hospitals and local urology clinics [was] as 
complete and rapid as possible. These data [were] entered into a relational database that 
[was] regularly downloaded into the PCaP Subject Tracking Database.”45 
3.3 Randomized Recruitment 
“Caucasian Americans account[ed] for a greater proportion of North Carolina 
patients than African Americans; therefore, a randomized recruitment procedure [was] 
used to generate comparable ascertainment and enrollment rates by race and state over 
the entire enrollment period. This sampling method improve[d] efficiency without 
compromising estimation of main effects and risk difference modification (additive scale 
interactions) by race, and appropriate analysis require[d] only that sampling probabilities 
are included as stratum-specific offset terms in some analytic models. To apply 
randomized recruitment, each ascertained case [was] assigned a random number and 
recruited only if that number [was] less than or equal to its race-specific sampling 
probability, which [was] 100% for African Americans and 44% for Caucasian 
Americans.”45 
3.4 Physician Notification  
“Recruitment beg[an] with a mailed request to the diagnosing physician for 
permission to contact their patient, as mandated by the North Carolina and Louisiana 
cancer registries. Written physician permission [were] not required; instead, physicians 
[were] given 3 weeks to notify PCaP if a patient should not be contacted for any reason, 
including ineligibility due to mental illness or impairment, nursing home residence, or 





information under a limited waiver of consent to identify and contact potential PCaP 
participants, was approved by the UNC and LSUHSC IRBs and DoD HSRRB.”45 
3.5 Enrollment 
“Patients with active or passive physician consent [were] sent an introductory 
letter and brochure describing PCaP. One week later an experienced enrollment specialist 
call[ed] to confirm eligibility, explain the study, answer questions, solicit participation, 
and schedule an in-home visit. Demographic and pathology report data (without 
personally identifiable information) [were] retained for cases who [could] not be 
contacted or who decline[d] participation, so that characteristics of non- participants 
[could] be compared with those of participants to assess potential selection bias. Reasons 
for declining participation [were] recorded when known. Enrollment specialists [were] 
required to make multiple attempts to contact each potential participant. If a valid phone 
number [could] not be identified, the patient’s urologist [was] asked to provide the patient 
with the PCaP introductory letter at his next appointment. Patients who [could] not be 
contacted within 90 days [were] sent a letter asking them to contact the study directly. If 
no contact [was] made within the next 30 days, the patient [was] classified as ‘‘unable to 
contact.’’45  
3.6 Data Collection 
“Prior to their participation in PCaP, all men signed an informed consent and 
provided signed release for medical records and tumor specimens. Research subjects 
were visited in their home by a trained registered nurse who conducted a structured 
interview, performed anthropometric measurements, and collected biospecimens. The 
majority of visits were completed on the average within four months of diagnosis. 





history of prostate cancer, cancer screening history, and prescribed and over-the-counter 
medications used in the prior two weeks, which included non-steroidal anti-inflammatory 
drugs (NSAIDs), vitamins and supplements. Men were asked to report usual dietary 
intake in the year prior to diagnosis using the National Cancer Institute Diet History 
Questionnaire (DHQ) modified to capture foods common to the geographic areas (e.g., 
Cajun and creole foods). The modified DHQ inquired about frequency of intake and 
usual portion size for 124 food items, and food preparation methods. Questionnaire 
responses were linked to the DHQ Nutrient Database through the Diet*Calc software, 
and intakes of macronutrients, micronutrients, and minerals, including calcium, were 
computed. After the in-home visit, medical records and tumor tissue samples were 
collected for each research subject who provided authorization for release.”18 
3.7 Biologic Sample Collection, Processing and Storage 
“To identify men for whom specimen collection may be contraindicated, 
participants [were] asked if they [had] a bleeding disorder, [were] taking blood thinners, 
had any prior problems giving blood, or [were] allergic to local anesthetics. Nurses 
[were] trained to respond to adverse events, and participants [were] observed for at least 
90 min after sample donation.  
Patient-specific barcode-labeled kits for biologic sample collection [were] 
prepared in advance. Biologic sample tracking by the PCaP Specimen Tracking Database 
[began] when sample labels [were] printed, and receipt of each sample [was] registered 
when it [was] scanned into the database after the study visit. After collection, samples 
[were] transported under appropriate conditions to UNC or LSUHSC tissue procurement 
facilities (TPF) or the UNC tissue culture facility (TCF). With the exception of yellow 





short-term storage at the LSUHSCTPF prior to monthly batch-shipping to the UNC TPF 
for long-term storage.”45 
3.8 Anthropometric Measurements 
“Weight (to the nearest 0.1 kg), height, and waist and hip circumferences (in cm) 
[were] measured after biologic sample collection using standardized instruments. 
Participants [were] asked their usual weight and height at age 25 and their weight 1 year 
prior to the visit.”45 
3.9 Study Questionnaires 
“Study nurses administer[ed] a series of structured questionnaires that solicit[ed] 
information regarding:  
Background characteristics: self-described race and ancestry, marital status, religion, 
education, income, tobacco use, physical activity. 
Occupation: current employment, occupation and industry; longest and second longest 
occupation and industry; military service; occupations associated with pesticide use. 
Family history: prostate cancer in first- and second- degree relatives. 
Health status: general health and comorbid conditions. 
Health care: usual sources of care, health insurance, traditional health beliefs, perceived 
access, and quality of care. 
Prostate cancer diagnosis and screening history: PSA tests, digital rectal exams, 
urinary and sexual symptoms, previous prostate biopsies. 
Medication survey: all prescription and over-the- counter medications and supplements 





Non-steroidal anti-inflammatory drugs (NSAIDs): frequency and duration of use for 
prescription and over-the-counter NSAIDs taken during the past 5 years at least once a 
month for 1 week or longer, with product name show cards to aid recall. 
Vitamins and supplements (including herbal products).”45 
3.10 Medical Records Retrieval and Abstraction 
 “Medical records [were] requested from the diagnosing physician of consenting 
participants. Trained staff use[d] a relational database designed specifically for PCaP to 
abstract information concerning comorbid conditions, family history of prostate cancer, 
urologic symptoms, indications for diagnostic examinations and biopsies, prostate cancer 
screening examinations, physical examinations, and laboratory assays at or near 
diagnosis, imaging examinations used in staging, clinical stage and grade (as recorded), 
and initial treatment information. In addition, abstractors independently derive[d] clinical 
stage according to a standardized protocol. Pathologic stage, grade and other 
prostatectomy data [were] recorded[ed] separately, when available. Approximately 10% 
of medical records [were] selected at random and abstracted to assess consistency 
between abstractors.”45  
4. Variables  
4.1 Outcome: Aggressive Prostate Cancer 
Participants were classified into three categories of aggressiveness at diagnosis 
based upon Gleason grade, clinical stage and PSA. The three categories are as follows: 
“High aggressive cases: Gleason sum ³ 8, or PSA >20 ng/ml at diagnosis, or Gleason 
sum = 7 AND stage T3-T4; low aggressive cases: Gleason sum <7 AND diagnosed at 
stage T1-T2 AND PSA <10 ng/ml at diagnosis; intermediate aggressive cases: all other 





aggressive cases who had Gleason sum =7 (4+3) were combined and referred to as the 
‘high aggressive’ case group. The comparison group, or control group, was created 
from a random sample of low aggressive cases with Gleason sum <7, stage T1-T2, and 
PSA<9 ng/ml.18   
4.2 Exposure:  
Main Exposure: GC Gene and Tag SNPs 
Tag SNPs (n=28) in the GC gene were identified using HapMap and were 
classified as National Institute of Environmental Health Sciences SNPs by identifying 
those with minor allele frequency (MAF) >5% and nonsynonymous polymorphisms 
possibly functionally relevant in AA and EA populations. Genotyping was performed 
using DNA extracted from whole blood samples and plated at either LSU or UNC before 
being sent to the Environmental Genomics Core at UNC where Illumina GoldenGate or 
Sequenom assays were utilized. Hardy-Weinberg equilibrium was calculated for each 
SNP to determine whether the genotype frequencies observed in the sample population 
differed from the expected frequencies. For this study, the focus is on the GC gene and its 
tag SNPs as the manuscript reporting results for other genes is currently under 
development. Table 3.1 reports the SNPs and genotype frequencies by race and case-
control status in PCaP. 
Vitamin D Assessment 
“During in-home visits, study nurses collected 6.5 ml of fasting venous blood into 
lavender top (EDTA) tubes which were wrapped in foil and transported on ice at 4°C to 
the Blood and Tissue Procurement Core Laboratory at LSU or the BioSpecimen 
Processing Facility at UNC. The majority of PCaP blood samples were processed to 





80°C. Plasma concentrations of 25(OH)D were determined using LC-MS/MS at 
Heartland Assays, Inc. PCaP plasma samples were stored at -80°C for up to eight years 
prior to measurement; concentrations of 25(OH)D3 in stored samples has been reported 
to be quite stable even at -20°C for up to ten years.”18 
4.3 Potential Confounders and/or Effect Modifiers  
Age: Included as a continuous variable in years for men between 40-79 years old. 
Race:  Included as a categorical variable dichotomized into AA and EA through self-
identification from the study questionnaires.  
Study Site: Sites included were from North Carolina (University of North Carolina) or 
Louisiana (Louisiana State University) post-hurricane Katrina. 
Family History: Included as a categorical variable dichotomized as follows: ‘No affected 
1st degree relative’ and ‘At least 1 affected 1st degree relative’.18 Obtained by self-report 
from study questionnaire.  
Education: Included as a categorical variable as follows: less than 8th grade or some high 
school, high school graduate or vocational/ technical school, some college or college 
graduate and, some graduate training or graduate/professional degree.18 Obtained by self-
report from study questionnaire. 
PSA screening history: Included as a categorical variable as 0, 1–7 and, >7 screenings.18 
Obtained by self-report from study questionnaire. 
BMI: During the study visit, measurements for weight, height and waist circumference 
were obtained by trained Registered Nurses. This variable was included as a continuous 
variable (kg/m2). 
Smoking Status: Included as a categorical variable as follows: non-smoker, former 





Alcohol Intake: Included as a continuous variable (g/day) and obtained by self-report 
from study questionnaire. 
NSAID Use: Included as a categorical variable dichotomized into ‘yes’ and ‘no’ 
responses. Obtained by self-report from study questionnaire.  
Physical Activity: Included as a continuous variable (MET-hours/week) through self-
reported physical activity from the study questionnaire. 
Season of blood draw: Included as a categorical variable as follows: winter (Dec 21-Mar 
22), spring (Mar 21- Jun 20), summer (Jun 21-Sep 20), and fall (Sep 21-Dec 20).18 
Total Energy Intake: Included as a continuous variable (kcal/day) through self-report 
from the study questionnaire.  
5. Analysis 
5.1 Missing Data 
Based on previous analyses from this dataset, we anticipated very few missing 
data points for outcome, exposure and covariates. Any participants with missing data in 
the variables of interest were excluded from analyses. 
5.2 Statistical Methods 
All analysis was completed using SAS version 9.4 statistical software. All tests 
were two-sided with significance level alpha=0.05. 
1.  Descriptive statistics were performed to describe the study population in 
terms of demographic and other characteristics by race and case status. Means 
and standard deviations, were reported for continuous variables and 
frequencies and proportions were reported for categorical variables.  
2. 25(OH)D was categorized as a 2-level variable, using a different cut-point for 





Based on the distributions the following cut-points were chosen: <15ng/ml for 
AA and <20ng/ml for EA. 
3. Univariate analysis of age and ancestry were modeled separately against each 
outcome, prostate cancer aggressiveness and 25(OH)D (2-level) to assess 
potential confounding. 
4. AIM 1: 
a. For Aim 1 specifically, rs7041 was relabeled to remain consistent with 
other studies.46 The ‘C’ and ‘A’ alleles were replaced with ‘G’ and ‘T’ 
alleles respectively. 
b. Combined genotypes of the GC gene were created based on the commonly 
studied rs7041 and rs4588 SNPs as previously described in other studies 
for Gc1s (rs7041-G and rs4588-C), GC1f (rs7041-T and rs4588-C) and 
Gc2 (rs7041-T and rs4588-A).46 The following combined genotypes were 
examined for this study: Gc1f-1f, Gc1s-1s, Gc1s-1f, Gc2-2, Gc2-1f, Gc2-
1s or Gc1f-x, and Gc2-x. Genotype frequencies and concentration of 
25(OH)D were considered when selecting the reference group among each 
race. For both races the second most frequent genotype and second highest 
25(OH)D concentration were selected as the reference group for the 
analysis of this aim.  
c. Means and standard deviations were calculated for 25(OH)D by the 
combined genotypes of the GC gene by race and prostate cancer 
aggressiveness.  





a.  Multivariable logistic regression was used to examine the association 
between combined genotypes and aggressive prostate cancer by race after 
adjusting for age and ancestry (African ancestry among AAs and 
European ancestry among EAs).  
b. Associations between each individual SNP (30 SNPs in AAs and 28 SNPs 
in EAs) and each 2-level outcome (aggressive prostate cancer or 25(OH)D 
level) were examined using logistic regression with adjustment for age and 
ancestry. Analyses were performed for three genetic models: additive, 
dominant and recessive models.  
For the additive model, the most frequent homozygous genotype 
(homozygous wildtype) was selected as the reference group. Mean and 
standard deviations of 25(OH)D were reported for each genotype in all 
models.  
c. The dominant model assumes that possessing one copy of the ‘dominant’ 
allele has the same effect as having two copies. The minor allele for each 
SNP was selected as the ‘dominant’ allele.  Heterozygotes were combined 
with homozygous variant carriers in comparison to the homozygous 
wildtype carriers, which were used as the reference group. An adjusted 
multivariable logistic regression was performed between each of the GC 
SNPs and both outcomes, aggressive prostate cancer and 25(OH)D 
concentrations. Mean and standard deviations of 25(OH)D were reported 
for each genotype category.  
d. The recessive model assumes that two copies of the ‘recessive’ allele are 





the ‘recessive’ allele.  Heterozygotes were combined with homozygous 
wildtype carriers and used as the reference group in comparison to the 
homozygous variant carriers. An adjusted multivariable logistic regression 
was performed between each of the GC SNPs and both outcomes, 
aggressive prostate cancer and 25(OH)D concentrations. Mean and 
standard deviations of 25(OH)D were reported for each genotype 
category.  
6. AIM 3: 
a. For each race separately, a polygenic score was created using the SNPs 
that were statistically significantly associated with 25(OH)D 
concentrations in the recessive model. All SNPs were checked for 
linkage disequilibrium (LD) by race using LDlink.47 For any SNPs that 
were in LD with each other, all but one were removed. Moving 
forward with the remaining SNPs by race, the genotype with the 
highest 25(OH)D concentration was given a score of 1 and the other 
genotype category was given a score of 0. Scores were added together 
to create a polygenic risk score for all participants, with higher scores 
representing higher 25(OH)D concentrations. 
b. Using an adjusted multivariable logistic regression, the association 
between the following variables was assessed: 1) polygenic risk score 
and prostate cancer aggressiveness; 2) 25(OH)D and prostate cancer 
aggressiveness stratified by polygenic risk score; and 3) polygenic risk 
score and prostate cancer aggressiveness stratified by 25(OH)D. 





whether the interaction term between the polygenic risk score and 
25(OH)D was statistically significant at p<0.10 in relation to the 





CHAPTER 4  
RESULTS 
 
Descriptive Characteristics of the Participants (Table 4.1) 
 After excluding research subjects with missing data, the final study population 
was 1181 male participants, of which 524 (44%) identified as AA and 657 (56%) as EA. 
As shown in Table 4.1, the average age of diagnosis was similar between both races (AA: 
61.5 ± 7.9yrs, EA: 64.1 ± 7.7yrs). The level of vitamin D (25(OH)D ng/ml) was higher 
on average among EA research subjects (24.7 ± 9.7ng/ml) than AA research subjects (17 
± 7.4ng/ml). In this study, AA participants with less than 15ng/ml and EA with less than 
20ng/ml of 25(OH)D were categorized as having low vitamin D status. High aggressive 
prostate cancer was more prevalent among AAs (41% vs 29% in EAs). Most participants 
of both races in the study did not have prior family history of prostate cancer in a first 
degree relative (71% for AAs and 75% for EAs). 
Confounding (Table 4.2) 
 Variables for age and ancestry (African and European) were assessed as possible 
confounders between prostate cancer aggressiveness, GC gene SNPs and vitamin D 
levels. Associations were examined between each variable (age and ancestry) and 
dichotomous 25(OH)D and prostate cancer aggressiveness. Age was significantly 
associated with both 25(OH)D and cancer aggressiveness in at least one or both races, 
therefore it was adjusted for in the final regression models for both races. African 





 European ancestry was not significantly associated with aggressive prostate cancer or 
25(OH)D levels. Despite these findings, previous literature and studies on prostate cancer 
have adjusted for ancestry, therefore both age and ancestry were included in their 
respective final models (African ancestry in AA models and European ancestry in EA 
models). 
Combined Genotypes of GCrs7041 and GCrs4588 (Table 4.3) 
Mean levels of 25(OH)D and the most common combined genotypes present 
within the study population varied by race. The most frequent combined genotypes were 
Gc1f-1f among AAs and GC1s-1s among EAs (Table 4.3). Mean levels of 25(OH)D 
were noticeably lower among AAs compared to EAs, with 18.7ng/ml and 27.4ng/ml 
being the highest mean values by combined genotype for AAs and EAs, respectively. 
None of the combined genotype categories were significantly associated with aggressive 
prostate cancer among AAs, and only one was significantly associated among EAs. EA 
individuals with the Gc2-1f combined genotype had a decreased risk of having high 
aggressive prostate cancer compared to those with the most frequent combined genotype, 
Gc1s-1s (OR: 0.38, 95%CI: 0.17, 0.85).  
GC Gene SNPs, 25(OH)D and Prostate Cancer Aggressiveness (Tables 4.4-4.16) 
Additive Model (Tables 4.4-4.7) 
 In the additive model, three SNPs among AAs (Table 4.4) and one SNP among 
EAs (Table 4.5) were significantly associated with high aggressive prostate cancer. The 
odds of high aggressive prostate cancer decreased by 45% for GCrs6817912 (OR: 0.55, 
95%CI: 0.31,0.98) among EAs, and 36% and 31% for GCrs16847028 and 
GCrs16847015 (rs16847028 OR: 0.64, 95%CI: 0.43, 0.96 and rs16847015 OR:0.69, 





GCrs222054 and GCrs16847015, the odds of high aggressive prostate cancer decreased 
by 37% for each copy of the ‘G’ allele (rs222054 OR: 0.63, 95%CI: 0.45, 0.87) among 
AAs. When examining the relationship between GC SNPs and risk of low vitamin D 
status, four SNPs among AAs (Table 4.6) and eight SNPs among EAs (Table 4.7) were 
statistically significant. For both races, the odds of low vitamin D increased for each copy 
of the ‘C’ allele in GCrs2282679 (AA: OR: 1.65, 95%CI:1.08, 2.51; EA: OR: 1.81, 
95%CI: 1.39, 2.36), the ‘G’ allele in GCrs17467825 (AA: OR: 1.85, 95%CI: 1.21, 2.83; 
EA: OR: 1.83, 95%CI: 1.41, 2.40), and the ‘A’ allele in GCrs3755967 (AA: OR: 1.67, 
95%CI: 1.11, 2.53; EA: OR: 1.86, 95%CI: 1.42, 2.43). Among AAs, the odds of low 
vitamin D decreased by 35% for each copy of the ‘G’ allele in GCrs222054 (OR: 0.65, 
95%CI: 0.47, 0.90). Four SNPs increased the odds of low vitamin D for each copy of the 
‘A’ allele (GCrs4588 OR: 1.89, 95%CI: 1.45, 2.48; GCrs7041 OR: 1.63, 95%CI: 1.27, 
2.09; GCrs705119 OR: 1.57, 95%CI: 1.22, 2.02; and GCrs705120 OR: 1.55, 95%CI: 
1.20, 1.98) and one SNP for each copy of the ‘G’ allele (GCrs222040 OR: 1.58, 95%CI: 
1.23, 2.03) among EAs. 
Recessive Model (Tables 4.8-4.11) 
When examining the association between the SNPs and prostate cancer 
aggressiveness using the recessive genetic model (Table 4.8-4.9), no associations were 
statistically significant in either race. However, results for the GCrs7041 SNP among 
EAs showed a suggestion of a protective association (OR: 0.63, 95%CI: 0.39, 1.02, p-
value:0.0579) with high aggressive prostate cancer (Table 4.9). 
In the recessive model, nine SNPs were found to be associated with low levels of 
25(OH)D. Among AAs with both copies of the recessive allele in the GCrs222054 SNP, 





heterozygote or homozygote wildtype carriers (OR: 0.33, 95%CI: 0.11, 0.998, p-value: 
0.0496) (Table 4.10). Eight SNPs were found to increase the odds of having low vitamin 
D status (below 20ng/mL) among EAs with both copies of the recessive allele compared 
to heterozygote or homozygote wildtype carriers (rs4588 OR: 2.80, 95%CI: 1.58, 4.97; 
rs7041 OR: 2.02, 95%CI: 1.35, 3.04; rs22040 OR: 2.04, 95%CI: 1.35, 3.08; rs705119 
OR: 2.15, 95%CI: 1.41, 3.27; rs705120 OR: 2.08, 95%CI: 1.36, 3.18; rs2282679 OR: 
2.64, 95%CI: 1.49, 4.66; rs3755967 OR: 2.65, 95%CI: 1.50, 4.67 and rs17467825 OR: 
2.64, 95%CI: 4.66, 3.08) (Table 4.11).  
Dominant Model (Tables 4.12-4.15) 
In the dominant model, when examining the association between GC SNPs and 
prostate cancer aggressiveness, only three SNPs had a statistically significant association. 
Among AAs (Table 4.12), individuals who were heterozygotes or homozygous variant in 
either the GCrs222054 or GCrs16847028 SNP had a decreased risk of developing high 
aggressive prostate cancer compared to those who were homozygous wildtype carriers 
(rs222054 OR: 0.55, 95%CI: 0.38, 0.80 and rs16847028 OR: 0.61, 95%CI: 0.39, 0.94). 
Only one SNP was statistically significantly associated with high aggressive prostate 
cancer among EAs (Table 4.13) using the dominant model (rs6817912 OR: 0.51, 95%CI: 
0.28,0.93), while there was a suggestion of an association with two other SNPs 
(Grs705125 OR: 0.68 95%CI: 0.47, 1.00 and GCrs3733359 OR: 0.56 95%CI: 0.31, 
1.01). In relation to levels of 25(OH)D, thirteen SNPs total were significantly associated 
with low levels of vitamin D among both races, five among AAs (Table 4.14) and eight 
among EAs (Table 4.15). Four of these SNPs (GCrs4588, GCrs2282679, GCrs3755967 
and GCrs17467825) were statistically significantly associated with low levels of vitamin 





individuals, being heterozygotes or homozygous variant carriers for rs4588,  rs2282679, 
rs3755967, and rs17467825 had an increased risk of having low levels of vitamin D 
compared to individuals who were homozygous wildtype carriers (AA: rs4588 OR:1.66, 
95%CI: 1.06, 2.61; rs2282679 OR: 1.86, 95%CI:1.13, 3.06; rs3755967 OR: 1.88, 
95%CI: 1.16, 3.05; rs17467825 OR: 2.05, 95%CI: 1.26, 3.36; EA: rs4588 OR: 2.05, 
95%CI: 1.45, 2.91; rs2282679 OR: 1.96, 95%CI:1.39, 2.77; rs3755967 OR: 2.03, 
95%CI: 1.43, 2.87; rs17467825 OR: 1.99, 95%CI: 1.40, 2.82).  The SNPs GCrs7041 
(OR:1.78, 95%CI: 1.19, 2.64), GCrs222040 (OR:1.65, 95%CI: 1.12, 2.44), GCrs705119 
(OR:1.57, 95%CI: 1.07, 2.30) and GCrs705120 (OR:1.55, 95%CI: 1.06, 2.26) had the 
same positive associations but only among EAs. Using the dominant model, only one 
SNP was statistically significantly associated with a decreased risk of low levels of 
vitamin D and it only occurred among AA individuals (rs222054 OR: 0.66, 95%CI: 0.45, 
0.96).  
Polygenic Risk Score (Table 4.16) 
Thirteen SNPs were statistically significantly associated with vitamin D status in 
the recessive model and were considered for creation of the polygenic risk score. All 
SNPs within each race were checked for LD and removed accordingly, with only two 
SNPs remaining for each race . The SNPs used to create the polygenic risk scores were 
GCrs4588 and GCrs222054 for AAs and GCrs4588 and GCrs7041 for EAs. Values of 
the polygenic risk score were 0, 1 or 2 depending on number of homozygous variant 
genotypes that were present for each of the two SNPs per race. Across both races, the 
average level of 25(OH)D increased as the score increased, with AAs still having a lower 
average 25(OH)D than EAs within each strata of polygenic risk score (Table 4.16). 





score=2 compared those with a score=0 (OR: 0.54, 95%CI: 0.31, 0.94), while there was 
no association among EAs.  
In stratified analyses (Table 4.16), there was a suggestion of an increased risk for 
low levels of vitamin D among AAs and a decreased risk among EAs for all levels of the 
polygenic risk scores, but none of these reached statistical significance. When assessing 
the relationship between the polygenic risk score and prostate cancer aggressiveness 
stratified by 25(OH)D, the risk of having high aggressive prostate cancer appeared to 
decrease among AA and increase among EA with a score above 0 across both levels of 
25(OH)D, but none reached statistical significance. Based on the interaction term p-
value, there was no significant interaction between the polygenic risk score and levels of 
vitamin D in relation to high aggressive prostate cancer (p= 0.83 for AAs and 0.96 for 
EAs). 
Summary of statistically significant results (Tables 4.17 and 4.18) 
A summary of the results for the SNPs which had at least one statistically 
significant association across the three different genetic models can be found in Tables 
4.17 (AAs) and 4.18 (EAs). The written summary of these results can be found in the 





Table 4.1 Study participant demographics by race 




Age, mean (SD) 61.5 (7.9) 64.1 (7.7) 
African Ancestry, mean (SD)a 0.90 (0.15) - 
European Ancestry, mean (SD)a - 0.97 (0.07) 
25(OH)D, mean (SD)b 17.6 (7.4) 24.7 (9.7) 
25(OH)D, n (%)c     
High 311 (59) 469 (71) 
Low 213 (41) 188 (29) 
PCa Aggressiveness, n (%)d     
High 217 (41) 187 (28) 
Low 307 (59) 470 (72) 
Family history in first degree 
relative, n (%)     
Yes 141 (29) 154 (25) 
No 349 (71) 467 (75) 
a continuous variable, African ancestry was only included in AA analysis and 
European ancestry was only included in EA analysis 
b continuous variable  
c categorical variable, <15ng/ml for AA and 20ng/ml for EA is considered low 
d defined as the severity of the cancer at diagnosis based on combinations of the 
Gleason score, morphologic stage, and PSA as follows: high aggressive, Gleason sum 
≥ 8 OR PSA > 20 ng/mL OR Gleason sum = 7 (4 +3) OR Gleason sum = 7 and stage 





   
Table 4.2 Assessment of confounding for age and ancestry 






(n=524)  (n= 657) 
Agea     
PCa aggressivenessb 0.0119 <.0001 
25(OH)Db 0.0398 0.8924 
African Ancestrya     
PCa aggressivenessb 0.7993 - 
25(OH)Db 0.0357 - 
European Ancestrya     
PCa aggressivenessb - 0.5720 
25(OH)Db - 0.7955 
a continuous variable  
b 2-level categorical variables; comparison group are cases for aggressiveness and 








Table 4.3 Combined rs7041 and rs4588 genotypes by race  
African Americans   Aggressiveness (n)     
Genotype rs7041 rs4588 High Low 
Mean 25(OH)D 
(SD) OR (95%CI)* 
Gc1f-1f  TT CC 109 162 17.5 (7.46) 1.0 (ref) 
Gc1s-1s GG CC 7 14 17.3 (7.18) 0.74 (0.29, 1.90) 
Gc1s-1f TG CC 56 73 18.7 (7.74) 1.14 (0.75, 1.74) 
Gc2-2 TT AA 6 5 15.2 (8.33) 1.78 (0.53, 5.99) 
Gc2-1f TT CA 28 36 16.4 (6.96) 1.16 (0.67, 2.00) 
Gc2-1s or 
Gc1f-x 
TG CA 10 11 17.0 (5.32) 1.35 (0.56, 3.29) 
Gc2-x TG AA 0 1 17.0 (-) 
<0.001 (<0.001, 
>999.9) 
European Americans Aggressiveness (n)     
Genotype rs7041 rs4588 High Low 
Mean 25(OH)D 
(SD) OR (95%CI)* 
Gc1s-1s GG CC 58 138 27.4 (13.5) 1.0 (ref) 
Gc1f-1f  TT CC 1 10 28.5 (7.21) 0.24 (0.03, 1.90) 
Gc1s-1f TG CC 41 74 25.5 (7.17) 1.32 (0.80, 2.15) 
Gc2-2 TT AA 17 35 21.2 (7.06) 1.16 (0.60, 2.23) 
Gc2-1f TT CA 8 50 22.2 (7.28) 0.38 (0.17, 0.85) 
Gc2-1s or 
GC1f-x TG CA 60 160 23.2 (6.84) 0.89 (0.58, 1.37) 
Gx2-x TG AA - - - - 








Table 4.4. Additive model - Genotype frequencies and association between SNPs and aggressive 
prostate cancer among African Americans 
  
Gene + SNP rs# Genotype African American (N = 524) case/control OR, 95% CI* P-value* 
GCrs4588 CC 172/249 Ref Ref 
  AC 38/47 1.15 (0.72, 1.85) 0.92 
  AA 6/6  1.43 (0.45, 4.57) 0.63 
Additive (per allele)     1.21 (0.68, 2.16) 0.52 
GCrs7041 AA 143/208 Ref Ref 
  AC 67/85 1.14 (0.77, 1.68) 0.31 
  CC 7/14 0.71 (0.27, 1.87) 0.41 
Additive (per allele)     1.01 (0.73, 1.40) 0.95 
GCrs188812 AA 158/220 Ref Ref 
  AT 56/76 1.03 (0.69, 1.55) 0.14 
  TT 3/11 0.35 (0.10, 1.28) 0.11 
Additive (per allele)     0.87 (0.62, 1.23) 0.44 
GCrs222016 GG 50/92 Ref Ref 
  AG 111/144 1.41 (0.92, 2.16) 0.40 
  AA 56/71 1.46 (0.88, 2.42) 0.33 
Additive (per allele)     1.21 (0.94, 1.56) 0.13 
GCrs222023 GG 69/99 Ref Ref 
  AG 104/134 1.09 (0.72, 1.64) 0.38 
  AA 39/65 0.86 (0.51, 1.44) 0.40 
Additive (per allele)     0.94 (0.73, 1.22) 0.65 








  AG 106/153 0.90 (0.61, 1.33) 0.97 
  AA 33/52 0.82 (0.48, 1.40) 0.55 
Additive (per allele)     0.90 (0.70, 1.17) 0.44 
GCrs222049 CC 158/236 Ref Ref 
  CG 52/66 1.16 (0.76, 1.77) 0.51 
  GG 7/5 2.16 (0.67, 6.99) 0.25 
Additive (per allele)     1.25 (0.88, 1.78) 0.21 
GCrs222054 CC 156/179 Ref Ref 
  CG 54/115 0.54 (0.36, 0.79) 0.14 
  GG 7/13 0.69 (0.27, 1.78) 0.89 
Additive (per allele)     0.63 (0.45, 0.87) 0.01 
GCrs705117 GG 105/165 Ref Ref 
  AG 89/113 1.23 (0.84, 1.79) 0.66 
  AA 23/29 1.26 (0.67, 2.35) 0.68 
Additive (per allele)     1.16 (0.88, 1.53) 0.29 
GCrs705119 AA 145/214 Ref Ref 
  AC 67/81 1.22 (0.82, 1.82) 0.17 
  CC 5/12 0.62 (0.20, 1.89) 0.30 
Additive (per allele)     1.06 (0.75, 1.48) 0.75 
GCrs705120 CC 53/84 Ref Ref 
  AC 106/143 1.16 (0.76, 1.78) 0.65 
  AA 54/76 1.14 (0.70, 1.88) 0.77 
Additive (per allele) AA 54/76 1.07 (0.84, 1.37) 0.59 
GCrs705124  GG 127/171 Ref Ref 
  AG 79/110 0.98 (0.68, 1.43) 0.30 








Additive (per allele)     0.87 (0.65, 1.15) 0.32 
GCrs705125 CC 67/110 Ref Ref 
  AC 105/136 1.28 (0.85, 1.91) 0.47 
  AA 45/60 1.25 (0.75, 2.07) 0.66 
Additive (per allele)     1.13 (0.88, 1.45) 0.33 
GCrs1352845 AA 133/181 Ref Ref 
  AG 57/81 0.94 (0.62, 1.41) 0.85 
  GG 27/45 0.81 (0.47, 1.38) 0.49 
Additive (per allele)     0.91 (0.71, 1.16) 0.44 
GCrs1491710 AA 86/111 Ref Ref 
  AC 96/148 0.80 (0.54, 1.19)  0.45 
  CC 32/47 0.86 (0.50, 1.48)  0.87 
Additive (per allele)     0.90 (0.69, 1.16) 0.42 
GCrs1873590 AA 174/242 Ref Ref 
  AG 42/60 0.98 (0.63, 1.54) 0.28 
  GG 1/5 0.27 (0.03, 2.34) 0.24 
Additive (per allele)     0.88 (0.59, 1.32) 0.53 
GCrs2282679 AA 180/268 Ref Ref 
  AC 33/33 1.45 (0.86, 2.45) 0.29 
  CC 4/6 0.89 (0.24, 3.22) 0.64 
Additive (per allele)     1.22 (0.81, 1.85) 0.35 
GCrs3733359 GG 123/176 Ref Ref 
  AG 73/112 0.93 (0.64, 1.35) 0.14 
  AA 21/18 1.68 (0.85, 3.31) 0.10 
Additive (per allele)     1.12 (0.85, 1.48) 0.42 








  AG 35/38 1.36 (0.82, 2.24) 0.36 
  AA 4/6 0.88 (0.24, 3.20) 0.67 
Additive (per allele)     1.18 (0.79, 1.77) 0.43 
GCrs3775152 CC 109/160 Ref Ref 
  AC 92/111 1.23 (0.84, 1.78) 0.05 
  AA 16/36 0.64 (0.34, 1.22) 0.08 
Additive (per allele)     0.94 (0.72, 1.23) 0.65 
GCrs4364228 AA 86/113 Ref Ref 
  AG 93/146 0.82 (0.56, 1.21)  0.27 
  GG 37/48 1.02 (0.61, 1.71)  0.63 
Additive (per allele)     0.97 (0.75, 1.25) 0.81 
GCrs6817912  GG 177/244 Ref Ref 
  AG 39/58 0.94 (0.60, 1.48) 0.34 
  AA 1/5 0.29 (0.03, 2.52) 0.28 
Additive (per allele)     0.85 (0.57, 1.29) 0.45 
GCrs10488854 GG 164/242 Ref Ref 
  AG 49/61 1.18 (0.77, 1.81) 0.97 
  AA 4/4 1.43 (0.35, 5.86) 0.70 
Additive (per allele)     1.18 (0.81 1.73) 0.39 
GCrs16846912 AA 138/177 Ref Ref 
  AG 70/113 0.79 (0.55, 1.16) 0.90 
  GG 9/17 0.68 (0.29, 1.57) 0.51 
Additive (per allele)     0.81 (0.60, 1.09) 0.16 
GCrs16847015 CC 162/207 Ref Ref 
  AC 53/88 0.78 (0.53, 1.17) 0.23 








Additive (per allele)     0.69 (0.49, 0.98) 0.04 
GCrs16847019 GG 166/237 Ref Ref 
  AG 49/67 1.04 (0.68, 1.60) 0.83 
  AA 2/3 0.88 (0.15, 5.37) 0.87 
Additive (per allele)     1.03 (0.69, 1.52) 0.90 
GCrs16847024 GG 182/269 Ref Ref 
  AG 31/35 1.27 (0.75, 2.14) 0.90 
  AA 4/3 1.81 (0.40, 8.28) 0.54 
Additive (per allele)     1.29 (0.83, 2.01) 0.26 
GCrs373749 GG 149/216 Ref Ref 
  AG 62/81 1.10 (0.74, 1.63) 0.69 
  AA 6/9 0.94 (0.32, 2.71) 0.83 
Additive (per allele)     1.05 (0.75, 1.47) 0.76 
GCrs16847028 GG 179/227 Ref Ref 
  AG 36/75 0.61 (0.39, 0.95) 0.63 
  AA 2/5 0.58 (0.11, 3.06) 0.73 
Additive (per allele)     0.64 (0.43, 0.96) 0.03 
GCrs17467825 AA 176/258 Ref Ref 
  AG 35/36 1.43 (0.86, 2.39) 0.17 
  GG 3/6 0.63 (0.15, 2.59) 0.38 
Additive (per allele)     1.16 (0.77, 1.77) 0.47 








Table 4.5. Additive model - Genotype frequencies and association between SNPs and aggressive prostate 
cancer among European Americans 
  
Gene + SNP rs# Genotype European American (N = 657) cases/control OR, 95% CI* P-value* 
GCrs4588 CC 100/222 Ref Ref 
  AC 69/210 0.76 (0.53, 1.10) 0.16 
  AA 17/35 1.05 (0.55, 1.99) 0.55 
Additive (per allele) 
  
0.90 (0.69, 1.19) 0.46 
GCrs7041 CC 58/138 Ref Ref 
  AC 102/234 1.04 (0.70, 1.54) 0.16 
  AA 26/98 0.65 (0.38, 1.11) 0.06 
Additive (per allele) 
  
0.84 (0.65, 1.08) 0.18 
GCrs188812 AA 156/377 Ref Ref 
  AT 26/87 0.75 (0.46, 1.21) 0.15 
  TT 5/6 1.71 (0.50, 5.88) 0.28 
Additive (per allele) 
  
0.91 (0.61, 1.35) 0.63 
GCrs222016 AA 140/328 Ref Ref 
  AG 42/134 0.73 (0.49, 1.10) 0.21 
  GG 5/8 1.29 (0.40, 4.15) 0.49 
Additive (per allele) 
  
0.83 (0.59, 1.18) 0.31 
GCrs222023 GG 168/402 Ref Ref 
  AG 16/53 0.68 (0.37, 1.25) 0.98 
  AA 0/2 <0.001 (<0.001, >999.9) 0.97 
Additive (per allele) 
  
0.65 (0.36, 1.17) 0.15 








  AG 101/233 1.02 (0.69, 1.51) 0.23 
  GG 26/95 0.67 (0.39, 1.15) 0.09 
Additive (per allele) 
  
0.85 (0.66, 1.10) 0.21 
GCrs222049 CC 164/412 Ref Ref 
  CG 22/58 0.96 (0.56, 1.63) 0.97 
  GG 1/0 >999.9 (<0.001, >999.9) 0.97 
Additive (per allele) 
  
1.06 (0.64, 1.77) 0.82 
GCrs222054 CC 100/235 Ref Ref 
  CG 72/198 0.91 (0.63, 1.31) 0.68 
  GG 15/37 0.99 (0.51, 1.92) 0.90 
Additive (per allele) 
  
0.96 (0.73, 1.26) 0.76 
GCrs705117 AA 138/335 Ref Ref 
  AG 48/125 0.95 (0.64, 1.40) 0.26 
  GG 1/10 0.25 (0.03, 2.02) 0.20 
Additive (per allele) 
  
0.85 (0.59, 1.22) 0.38 
GCrs705119 CC 61/147 Ref Ref 
  AC 101/235 1.05 (0.72, 1.55) 0.23 
  AA 25/88 0.72 (0.42, 1.24) 0.15 
Additive (per allele) 
  
0.89 (0.69, 1.14) 0.35 
GCrs705120 CC 63/151 Ref Ref 
  AC 99/231 1.05 (0.72, 1.55) 0.25 
  AA 25/87 0.73 (0.42, 1.25) 0.17 
Additive (per allele) 
  
0.89 (0.69, 1.15) 0.37 
GCrs705124 GG 155/377 Ref Ref 
  AG 25/83 0.77 (0.50, 1.26) 0.08 








Additive (per allele) 
  
1.01 (0.69, 1.47) 0.97 
GCrs705125 AA 136/302 Ref Ref 
  AC 45/151 0.67 (0.45, 0.99) 0.33 
  CC 6/15 0.82 (0.31, 2.20) 1.00 
Additive (per allele) 
  
0.75 (0.54, 1.04) 0.08 
GCrs1352845 AA 163/392 Ref Ref 
  AG 19/64 0.70 (0.40, 1.23) 0.87 
  GG 4/14 0.56 (0.18, 1.76) 0.50 
Additive (per allele) 
  
0.73 (0.48, 1.10) 0.13 
GCrs1491710 AA 185/462 Ref Ref 
  AC 2/8 0.51 (0.09, 2.72) 0.43 
  CC 0/0 - - 
Additive (per allele) 
  
0.51 (0.10, 2.72) 0.43 
GCrs1873590 AA 186/467 Ref Ref 
  AG 0/3 <0.001 (<0.001, >999.9) 0.99 
  GG 0/0 - - 
Additive (per allele) 
  
<0.001 (<0.001, >999) 0.99 
GCrs2282679 AA 101/231 Ref Ref 
  AC 68/203 0.80 (0.55, 1.15) 0.16 
  CC 18/35 1.16 (0.62, 2.17) 0.41 
Additive (per allele) 
  
0.95 (0.72, 1.25) 0.71 
GCrs3733359 GG 171/405 Ref Ref 
  AG 15/63 0.54 (0.29, 0.98) 0.23 
  AA 1/2 1.46 (0.13, 16.48) 0.58 
Additive (per allele) 
  
0.60 (0.34, 1.06) 0.08 








  AG 69/213 0.75 (0.52, 1.08) 0.11 
  AA 18/35 1.12 (0.60, 2.11) 0.40 
Additive (per allele) 
  
0.92 (0.70, 1.21) 0.53 
GCrs3775152 AA 
   
  AC 
   
  CC 
   
Additive (per allele) 
    
GCrs4364228 AA 162/405 Ref Ref 
  AG 24/63 0.95 (0.56, 1.58) 0.84 
  GG 1/2 1.17 (0.10, 13.29) 0.88 
Additive (per allele) 
  
0.96 (0.60, 1.56) 0.88 
GCrs6817912  GG 172/402 Ref Ref 
  AG 14/66 0.49 (0.26, 0.90) 0.19 
  AA 1/2 1.44 (0.13, 16.27) 0.56 
Additive (per allele) 
  
0.55 (0.31 0.98) 0.04 
GCrs10488854 GG 185/465 Ref Ref 
  AG 2/5 0.70 (0.12, 4.21) 0.70 
  AA 0/0 - - 
Additive (per allele) 
  
0.70 (0.12, 4.21) 0.70 
GCrs16846912 AA 187/467 Ref Ref 
  AG 0/3 <0.001 (<0.001, >999.9) 0.99 
  GG 0/0 - - 
Additive (per allele) 
  
<0.001 (<0.001, >999) 0.99 
GCrs16847015 CC 172/423 Ref Ref 
  AC 15/45 0.80 (0.43, 1.48) 0.98 








Additive (per allele) 
  
0.75 (0.41, 1.37) 0.34 
GCrs16847019 GG 187/464 Ref Ref 
  AG 0/6 <0.001 (<0.001, >999.9) 0.98 
  AA 0/0 - - 
Additive (per allele) 
  
<0.001 (<0.001, >999) 0.98 
GCrs16847024 GG 185/467 Ref Ref 
  AG 2/3 1.07 (0.16, 7.10) 0.95 
  AA 0/0 - - 
Additive (per allele) 
  
1.07 (0.16, 7.10) 0.95 
GCrs373749 GG 
   
  AG 
   
  AA 
   
Additive (per allele) 
    
GCrs16847028 GG 155/372 Ref Ref 
  AG 27/92 0.72 (0.45, 1.16) 0.12 
  AA 5/6 1.72 (0.50, 5.93) 0.26 
Additive (per allele) 
  
0.88 (0.60, 1.30) 0.52 
GCrs17467825 AA 100/218 Ref Ref 
  AG 69/208 0.76 (0.52, 1.09) 0.13 
  GG 18/35 1.10 (0.59, 2.07) 0.45 
Additive (per allele) 
  
0.92 (0.70, 1.20) 0.53 









Table 4.6 Additive Model - Genotype frequencies by 25(OH)D cut-point and association between SNPs and 
vitamin D status among African Americans 
 
Gene + SNP rs# Genotype 
African American  
(N = 524) 
below/above* 
25(OH)D 
Mean, SD OR, 95% CI* P-value* 
GCrs4588 CC 163/258 17.8 (7.54)  Ref Ref 
  AC 41/44 16.6 (6.57) 1.57 (0.97, 2.52) 0.94 
  AA  7/5 15.3 (7.96) 2.60 (0.79, 8.53) 0.23 
Additive (per allele)       1.64 (0.90, 2.98) 0.11 
GCrs7041 AA 150/201 17.2 (7.36) Ref Ref 
  AC 54/98 18.4 (7.41) 0.79 (0.53, 1.18) 0.24 
  CC 9/12 17.3 (7.18) 1.23 (0.49, 3.11) 0.49 
Additive (per allele)       0.91 (0.65, 1.26) 0.56 
GCrs188812 AA 152/226 17.8 (7.50) Ref Ref 
  AT 56/76 16.9 (7.05) 1.07 (0.72, 1.61) 0.63 
  TT 5/9 16.4 (7.02) 0.83 (0.27, 2.55) 0.70 
Additive (per allele)       1.02 (0.72, 1.43) 0.93 
GCrs222016 GG 54/88 17.6 (7.42) Ref Ref 
  AG 113/142 17.4 (7.71) 1.39 (0.91, 2.13) 0.08 
  AA 46/81 17.9 (6.64) 1.04 (0.63, 1.73) 0.56 
Additive (per allele)       1.03 (0.80, 1.32) 0.81 
GCrs222023 GG 62/106 17.6 (6.45) Ref Ref 
  AG 103/135 17.4 (6.85) 1.25 (0.82, 1.88) 0.24 








Additive (per allele)       1.02 (0.80, 1.32) 0.85 
GCrs222040 GG 74/105 17.4 (7.52) Ref Ref 
  AG 106/153 17.2 (7.06) 1.02 (0.69, 1.51) 0.70 
  AA 32/53 18.9 (7.92) 0.90 (0.53, 1.54) 0.65 
Additive (per allele)       0.96 (0.74, 1.25) 0.78 
GCrs222049 CC 165/229 17.4 (7.47) Ref Ref 
  CG 46/72 17.6 (7.06) 0.87 (0.57, 1.33) 0.23 
  GG 2/10 21.3 (6.58) 0.27 (0.06, 1.23) 0.11 
Additive (per allele)       0.76 (0.52, 1.09) 0.14 
GCrs222054 CC 148/187 17.1 (7.58) Ref Ref 
  CG 61/108 18.1 (6.91) 0.71 (0.49, 1.05) 0.40 
  GG 4/16 19.3 (7.44) 0.29 (0.09, 0.90) 0.06 
Additive (per allele)       0.65 (0.47, 0.90) 0.01 
GCrs705117 GG 110/160 17.4 (7.54) Ref Ref 
  AG 79/123 17.8 (7.37) 1.02 (0.70, 1.49) 0.34 
  AA 24/28 17.0 (6.54) 1.55 (0.82, 2.90) 0.16 
Additive (per allele)       1.15 (0.88, 1.52) 0.31 
GCrs705119 AA 153/206 17.3 (7.56) Ref Ref 
  AC 53/95 18.0 (7.01) 0.80 (0.53, 1.20) 0.31 
  CC 7/10 18.2 (6.58) 1.21 (0.42, 3.44) 0.57 
Additive (per allele)       0.89 (0.63, 1.27) 0.51 
GCrs705120 CC 57/80 17.6 (7.54) Ref Ref 
  AC 100/149 17.5 (7.29) 0.95 (0.62, 1.45) 1.00 
  AA 52/78 17.6 (7.21) 0.90 (0.55, 1.47) 0.69 
Additive (per allele)       0.95 (0.74, 1.21) 0.66 








  AG 73/116 17.6 (7.23) 0.81 (0.56,1.19) 0.83 
  AA 12/25 18.1 (7.16) 0.60 (0.29, 1.24) 0.26 
Additive (per allele)       0.79 (0.60, 1.06) 0.11 
GCrs705125 CC 74/103 17.6 (7.98)  Ref Ref 
  AC 99/142 17.5 (7.40) 1.04 (0.70, 1.55) 0.66 
  AA 39/66 17.7 (6.26) 0.92 (0.55, 1.53) 0.65 
Additive (per allele)       0.97 (0.75, 1.24) 0.80 
GCrs1352845 AA 129/185 17.3 (7.02) Ref Ref 
  AG 47/91 18.6 (8.01) 0.72 (0.47, 1.10) 0.02 
  GG 37/35 16.4 (7.74) 1.44 (0.86, 2.43) 0.04 
Additive (per allele)       1.08 (0.84, 1.37) 0.56 
GCrs1491710 AA 73/124 18.1 (7.36) Ref Ref 
  AC 101/143 17.5 (7.14) 1.18 (0.79, 1.74) 0.74 
  CC 39/40 15.9 (7.85) 1.57 (0.92, 2.67) 0.14 
Additive (per allele)       1.24 (0.96, 1.60) 0.11 
GCrs1873590 AA 164/252 17.8 (7.41) Ref Ref 
  AG 44/58 16.7 (7.11) 1.09 (0.70, 1.70) 0.12 
  GG 5/1 9.92 (4.33) 7.57 (0.87, 66.0) 0.07 
Additive (per allele)       1.29 (0.87, 1.93) 0.20 
GCrs2282679 AA 174/274 17.8 (7.50) Ref Ref 
  AC 34/32 16.1 (6.21) 1.85 (1.09, 3.14) 0.47 
  CC 5/5 16.0 (8.24) 1.90 (0.53, 6.80) 0.61 
Additive (per allele)       1.65 (1.08, 2.51) 0.02 
GCrs3733359 GG 125/174 17.3 (6.99) Ref Ref 
  AG 70/115 18.2 (7.81) 0.83 (0.57, 1.21) 0.40 








Additive (per allele)       0.92 (0.70, 1.22) 0.56 
GCrs3755967 GG 170/271 17.8 (7.46) Ref Ref 
  AG 38/35 16.3 (6.63) 1.88 (1.13, 3.12) 0.45 
  AA 5/5 16.0 (8.24) 1.91 (0.53, 6.86) 0.61 
Additive (per allele)       1.67 (1.11, 2.53) 0.01 
GCrs3775152 CC 99/170 18.2 (7.22) Ref Ref 
  AC 91/112 16.9 (7.50) 1.32 (0.91, 1.93) 0.47 
  AA 23/29 17.1 (7.56) 1.29 (0.70, 2.38) 0.70 
Additive (per allele)       1.20 (0.92, 1.57) 0.18 
GCrs4364228 AA 81/118 17.5 (7.41) Ref Ref 
  AG 98/141 17.2 (7.09) 0.98 (0.66, 1.44) 0.89 
  GG 34/51 18.4 (8.02) 0.91 (0.54, 1.54) 0.73 
Additive (per allele)       0.96 (0.75, 1.23) 0.75 
GCrs6817912  GG 173/248 17.4 (7.24) Ref Ref 
  AG 36/61 18.2 (7.50) 0.82 (0.52, 1.30) 0.17 
  AA 4/2 18.4 (14.12) 2.58 (0.47, 14.4) 0.23 
Additive (per allele)       0.95 (0.64, 1.43) 0.82 
GCrs10488854 GG 162/244 17.8 (7.47) Ref Ref 
  AG 46/64 16.9 (7.12) 1.05 (0.68, 1.62) 0.36 
  AA 5/3 15.01 (5.67) 2.38 (0.56, 10.2) 0.26 
Additive (per allele)       1.15 (0.79, 1.69) 0.45 
GCrs16846912 AA 124/191 17.6 (7.22) Ref Ref 
  AG 77/106 17.4 (7.49) 1.09 (0.75, 1.59) 0.96 
  GG 12/14 17.7 (8.69) 1.23 (0.55, 2.77) 0.69 
Additive (per allele)       1.10 (0.82, 1.48) 0.53 








  AC 56/85 18.0 (7.99) 0.94 (0.63, 1.40) 0.14 
  AA 9/5 15.7 (9.61) 2.38 (0.78, 7.31) 0.12 
Additive (per allele)       1.11 (0.79, 1.55) 0.55 
GCrs16847019 GG 168/235 17.6 (7.36) Ref Ref 
  AG 43/73 17.3 (7.20) 0.77 (0.50, 1.19) 0.64 
  AA 2/3 22.4 (11.9) 0.96 (0.16, 5.83) 0.93 
Additive (per allele)       0.80 (0.54, 1.20) 0.28 
GCrs16847024 GG 181/270 17.6 (7.32) Ref Ref 
  AG 29/37 17.1 (7.62) 1.17 (0.69, 1.99) 0.82 
  AA 3/4 15.4 (9.16) 1.12 (0.25, 5.12) 0.97 
Additive (per allele)       1.14 (0.73, 1.77) 0.57 
GCrs373749 GG 147/218 17.6 (7.36) Ref Ref 
  AG 58/85 17.7 (7.49) 0.98 (0.66, 1.46) 0.69 
  AA 7/8 16.4 (6.70) 1.24 (0.44, 3.51) 0.67 
Additive (per allele)       1.03 (0.73, 1.43) 0.89 
GCrs16847028 GG 160/246 17.6 (7.27) Ref Ref 
  AG 49/62 17.4 (7.84) 1.23 (0.80, 1,88) 0.89 
  AA 4/3 14.6 (5.94) 1.70 (0.37, 7.76) 0.58 
Additive (per allele)       1.24 (0.85, 1.82) 0.26 
GCrs17467825 AA 166/268 17.8 (7.43) Ref Ref 
  AG 38/33 16.11 (6.81) 2.00 (1.20, 3.36) 0.58 
  GG 5/4 14.7 (7.47) 2.51 (0.65, 9.72) 0.41 
Additive (per allele)       1.85 (1.21, 2.83) 0.005 
* <15ng/ml = below 








Table 4.7 Additive Model - Genotype frequencies by 25(OH)D cut-point and association between SNPs and 
vitamin D status among European Americans 
 
Gene + SNP rs# Genotype 
European American  
(N = 657)  
below/above* 
25(OH)D 
Mean, SD OR, 95% CI P-value 
GCrs4588 CC 68/254 26.7 (11.5) Ref Ref 
  AC 91/188 23.0 (6.93) 1.81 (1.26, 2.62) 0.74 
  AA 26/26 21.2 (7.06) 3.77 (2.05, 6.92) 0.001 
Additive (per allele)       1.89 (1.45, 2.48) <.0001 
GCrs7041 CC 41/155 27.3 (13.5) Ref Ref 
  AC 96/240 24.0 (7.02) 1.51 (0.99, 2.29) 0.67 
  AA 51/73 22.2 (7.35) 2.65 (1.61, 4.35) 0.0003 
Additive (per allele)       1.63 (1.27, 2.09) 0.0001 
GCrs188812 AA 148/385 24.8 (9.96) Ref Ref 
  AT 37/76 23.9 (8.40) 1.27 (0.82, 1.97) 0.53 
  TT 3/8 25.9 (6.40) 0.98 (0.26, 3.75) 0.84 
Additive (per allele)       1.18 (0.81, 1.71) 0.39 
GCrs222016 AA 134/334 24.6 (10.21) Ref Ref 
  AG 50/126 24.7 (8.23) 0.99 (0.67, 1.45) 0.85 
  GG 4/9 25.7 (6.57) 1.11 (0.34, 3.68) 0.85 
Additive (per allele)       1.01 (0.72, 1.41) 0.98 
GCrs222023 GG 168/402 24.45 (9.84) Ref Ref 
  AG 17/52 25.5 (8.09) 0.77 (0.43, 1.38) 0.36 
  AA 1/1 25.0 (10.3) 2.42 (0.15, 38.9) 0.48 








GCrs222040 AA 44/157 27.2 (13.4) Ref Ref 
  AG 94/240 24.0 (7.03) 1.39 (0.92, 2.10) 0.46 
  GG 50/71 22.2 (7.41) 2.53 (1.54, 4.14) 0.0004 
Additive (per allele)       1.58 (1.23, 2.03) 0.0003 
GCrs222049 CC 167/409 24.7 (9.96) Ref Ref 
  CG 21/59 24.4 (7.22) 0.87 (0.51, 1.48) 0.98 
  GG 0/1 29.6 (-) <0.001 (<0.001, >999.9) 0.98 
Additive (per allele)       0.85 (0.50, 1.42) 0.53 
GCrs222054 CC 101/234 24.2 (8.27) Ref Ref 
  CG 77/193 24.8 (11.4) 0.93 (0.65, 1.32) 0.34 
  GG 10/42 26.9 (7.73) 0.55 (0.27, 1.15) 0.13 
Additive (per allele)       0.83 (0.63, 1.09) 0.18 
GCrs705117 AA 139/334 24.7 (10.4) Ref Ref 
  AG 47/126 24.31 (7.38) 0.89 (0.61, 1.32) 0.65 
  GG 2/9 27.9 (7.62) 0.54 (0.11, 2.52) 0.47 
Additive (per allele)       086 (0.60, 1.22) 0.39 
GCrs705119 CC 47/161 27.0 (13.2) Ref Ref 
  AC 93/243 24.1 (7.01) 1.31 (0.88, 1.96) 0.26 
  AA 48/65 22.0 (7.51) 2.54 (1.55, 4.18) 0.0002 
Additive (per allele)       1.57 (1.22, 2.02) 0.0004 
GCrs705120 CC 49/165 26.8 (13.1) Ref Ref 
  AC 92/238 24.1 (7.01) 1.31 (0.88, 1.95) 0.30 
  AA 47/65 22.0 (7.53) 2.46 (1.50, 4.03) 0.0004 
Additive (per allele)       1.55 (1.20, 1.98) 0.0006 
GCrs705124  GG 150/382 24.8 (9.99) Ref Ref 








  AA 5/9 24.0 (7.17) 1.42 (0.47, 4.32) 0.58 
Additive (per allele)       1.12 (0.78, 1.62) 0.54 
GCrs705125 AA 124/314 24.8 (10.5) Ref Ref 
  AC 56/140 24.2 (7.62) 1.01 (0.70, 1.47) 0.45 
  CC 8/13 25.8 (9.67) 1.56 (0.63, 3.87) 0.34 
Additive (per allele)       1.10 (0.81, 1.49) 0.56 
GCrs1352845 AA 163/392 24.5 (9.93) Ref Ref 
  AG 17/66 25.9 (7.80) 0.61 (0.35, 1.08) 0.02 
  GG 8/10 24.3 (8.94) 1.95 (0.75, 5.04) 0.07 
Additive (per allele)       0.96 (0.65, 1.40) 0.82 
GCrs1491710 AA 183/464 24.7 (9.68) Ref Ref 
  AC 5/5 19.8 (6.41) 2.59 (0.71, 9.51) 0.15 
  CC - - - - 
Additive (per allele)       2.59 (0.71, 9.51) 0.15 
GCrs1873590 AA 185/468 24.7 (9.65) Ref Ref 
  AG 3/0 12.9 (3.62) <0.001 (<0.001, >999.9) 0.98 
  GG - - - - 
Additive (per allele)       >999 (>0.001, >999) 0.98 
GCrs2282679 AA 73/259 26.4 (11.4) Ref Ref 
  AC 89/182 23.1 (6.94) 1.74 (1.21, 2.50) 0.75 
  CC 26/27 21.3 (7.07) 3.44 (1.89, 6.26) 0.001 
Additive (per allele)       1.81 (1.39, 2.36) <.0001 
GCrs3733359 GG 168/408 24.6 (9.92) Ref Ref 
  AG 18/60 25.1 (7.51) 0.72 (0.41, 1.26) 0.09 
  AA 2/1 22.8 (8.24) 4.90 (0.44, 54.5) 0.16 








GCrs3755967 GG 69/253 26.7 (11.5) Ref Ref 
  AG 93/189 23.0 (6.92) 1.81 (1.26, 2.61) 0.84 
  AA 26/27 21.3 (7.07) 3.56 (1.95, 6.50) 0.001 
Additive (per allele)       1.86 (1.42, 2.43) <.0001 
GCrs3775152 AA         
  AC         
  CC         
Additive (per allele)           
GCrs4364228 AA 162/405 24.7 (9.98) Ref Ref 
  AG 25/62 24.45 (7.36) 1.01 (0.61, 1.66) 0.87 
  GG 1/2 23.7 (5.19) 1.26 (0.11, 13.9) 0.86 
Additive (per allele)       1.02 (0.64, 1.63) 0.92 
GCrs6817912  GG 166/408 24.6 (9.93) Ref Ref 
  AG 20/60 25.0 (7.50) 0.82 (0.48, 1.40) 0.13 
  AA 2/1 22.8 (8.24) 4.96 (0.45, 55.1) 0.17 
Additive (per allele)       0.96 (0.59, 1.57) 0.88 
GCrs10488854 GG 185/465 24.7 (9.67) Ref Ref 
  AG 3/4 19.67 (7.06) 1.88 (0.38, 9.35) 0.44 
  AA - - - - 
Additive (per allele)       1.88 (0.38, 9.35) 0.44 
GCrs16846912 AA 186/468 24.67 (9.67) Ref Ref 
  AG 2/1 20.2 (5.92) 5.16 (0.46, 57.5) 0.18 
  GG - - - - 
Additive (per allele)       5.16 (0.46, 57.5) 0.18 
GCrs16847015 CC 173/422 24.5 (9.84) Ref Ref 








  AA 1/1 25.0 (10.3) 2.47 (0.15, 39.8) 0.46 
Additive (per allele)       0.74 (0.40, 1.38) 0.33 
GCrs16847019 GG 186/465 24.7 (9.64) Ref Ref 
  AG 2/4 24.9 (12.1) 1.24 (0.23, 6.85) 0.80 
  AA - - - - 
Additive (per allele)       <0.001 (<0.001, >999) 0.80 
GCrs16847024 GG 188/464 24.7 (9.69) Ref Ref 
  AG 0/5 25.43 (2.73) <0.001 (<0.001, >999.9) 0.98 
  AA - - - - 
Additive (per allele)       0.76 (0.53, 1.10) 0.98 
GCrs373749 GG         
  AG         
  AA         
Additive (per allele)           
GCrs16847028 GG 146/381 24.9 (10.1) Ref Ref 
  AG 39/80 23.4 (7.34) 1.28 (0.83, 1.96) 0.52 
  AA 3/8 27.6 (9.39) 0.98 (0.26, 3.75) 0.83 
Additive (per allele)       1.18 (0.82, 1.71) 0.37 
GCrs17467825 AA 69/249 26.6 (11.5) Ref Ref 
  AG 91/186 23.0 (6.87) 1.77 (1.23, 2.56) 0.78 
  GG 26/27 21.3 (7.07) 3.50 (1.92, 6.39) 0.0009 
Additive (per allele)       1.83 (1.41, 2.40) <.0001 
* <20ng/ml = below 








Table 4.8 Recessive model - Genotype frequencies and association between SNPs and aggressive prostate 
cancer among African Americans 
 
Gene + SNP rs# Genotype African American (N = 524) case/control OR, 95% CI* P-value* 
GCrs4588 AC+CC 210/296 Ref Ref 
  AA 6/6 1.39 (0.44, 4.44) 0.58 
GCrs7041 AA+AC 210/293 Ref Ref 
  CC 7/14 0.68 (0.26, 1.76) 0.42 
GCrs188812 AA+AT 214/296 Ref Ref 
  TT 3/11 0.35 (0.10, 1.27) 0.11 
GCrs222016 AG+GG 161/236 Ref Ref 
  AA 56/71 1.17 (0.77, 1.76) 0.47 
GCrs222023 AG+GG 173/233 Ref Ref 
  AA 39/65 0.82 (0.52, 1.28) 0.37 
GCrs222040 AG+GG 184/254 Ref Ref 
  AA 33/52 0.87(0.54, 1.41) 0.58 
GCrs222049 CC+CG 210/302 Ref Ref 
  GG 7/5 2.09 (0.65, 6.72) 0.22 
GCrs222054 CC+CG 210/294 Ref Ref 
  GG 7/13 0.84 (0.33, 2.16) 0.72 
GCrs705117 AG+GG 194/278 Ref Ref 
  AA 23/29 1.13 (0.62, 2.06) 0.68 
GCrs705119 AA+AC 212/295 Ref Ref 
  CC 5/12 0.57 (0.19, 1.71) 0.32 








  AA 54/76 1.04 (0.69, 1.56) 0.86 
GCrs705124  AG+GG 206/281 Ref Ref 
  AA 11/26 0.59 (0.29, 1.23) 0.16 
GCrs705125 AC+CC 172/246 Ref Ref 
  AA 45/60 1.08 (0.69, 1.67) 0.75 
GCrs1352845 AA+AG 190/262 Ref Ref 
  GG 27/45 0.82 (0.49, 1.38) 0.46 
GCrs1491710 AA+AC 182/259 Ref Ref 
  CC 32/47 0.97 (0.60, 1.60) 0.92 
GCrs1873590 AA+AG 214/302 Ref Ref 
  GG 1/5 0.27 (0.03, 2.35) 0.24 
GCrs2282679 AA+AC 213/301 Ref Ref 
  CC 4/6 0.84 (0.23, 3.04) 0.79 
GCrs3733359 AG+GG 196/288 Ref Ref 
  AA 21/18 1.73 (0.89, 3.36) 0.10 
GCrs3755967 AG+GG 213/301 Ref Ref 
  AA 4/6 0.84 (0.23, 3.04) 0.79 
GCrs3775152 AC+CC 201/271 Ref Ref 
  AA 16/36 0.58 (0.31, 1.09) 0.09 
GCrs4364228 AA+AG 179/259 Ref Ref 
  GG 37/48 1.14 (0.71, 1.82) 0.60 
GCrs6817912  AG+GG 216/302 Ref Ref 
  AA 1/5 0.29 (0.03, 2.55) 0.27 
GCrs10488854 AG+GG 213/202 Ref Ref 
  AA 4/4 1.38 (0.34, 5.62) 0.66 








  GG 9/17 0.74 (0.32, 1.70) 0.47 
GCrs16847015 AC+CC 215/295 Ref Ref 
  AA 2/12 0.24 (0.05, 1.07) 0.06 
GCrs16847019 AG+GG 215/304 Ref Ref 
  AA 2/3 0.88 (0.14, 5.30) 0.88 
GCrs16847024 AG+GG 213/304 Ref Ref 
  AA 4/3 1.75 (0.38, 7.99) 0.47 
GCrs373749 AG+GG 211/297 Ref Ref 
  AA 6/9 0.91 (0.32, 2.61) 0.86 
GCrs16847028 AG+GG 215/302 Ref Ref 
  AA 2/5 0.64 (0.12, 3.37) 0.60 
GCrs17467825 AA+AG 211/294 Ref Ref 
  GG 3/6 0.60 (0.15, 2.45) 0.47 








Table 4.9 Recessive model - Genotype frequencies and association between SNPs and aggressive prostate 
cancer among European Americans 
 
Gene + SNP rs# Genotype European American (N = 657) cases/control OR, 95% CI* P-value* 
GCrs4588 AC+CC 169/432 Ref Ref 
  AA 17/35 1.19 (0.64, 2.21) 0.59 
GCrs7041 AC+CC 160/372 Ref Ref 
  AA 26/98 0.63 (0.39, 1.02) 0.06 
GCrs188812 AA+AT 182/464 Ref Ref 
  TT 5/6 1.79 (0.52, 6.16) 0.35 
GCrs222016 AA+AG 182/462 Ref Ref 
  GG 5/8 1.40 (0.44, 4.46) 0.57 
GCrs222023 AG+GG 184/455 Ref Ref 
  AA 0/2 <0.001 (<0.001, >999.999) 0.98 
GCrs222040 AA+AG 161/374 Ref Ref 
  GG 26/95 0.66 (0.41, 1.07) 0.09 
GCrs222049 CC+CG 186/470 Ref Ref 
  GG 1/0 <0.001 (<0.001, >999.999) 0.98 
GCrs222054 CC+CG 172/433 Ref Ref 
  GG 15/37 1.03 (0.55, 1.96) 0.92 
GCrs705117 AA+AG 186/460 Ref Ref 
  GG 1/10 0.26 (0.03, 2.04) 0.20 
GCrs705119 AC+CC 162/382 Ref Ref 
  AA 25/88 0.69 (0.43, 1.13) 0.14 








  AA 25/87 0.70 (0.43, 1.15) 0.16 
GCrs705124  AG+GG 180/460 Ref Ref 
  AA 7/7 2.20 (0.74, 6.54) 0.15 
GCrs705125 AA+AC 181/453 Ref Ref 
  CC 6/15 0.92 (0.34, 2.44) 0.86 
GCrs1352845 AA+AG 182/456 Ref Ref 
  GG 4/14 0.59 (0.19, 1.83) 0.36 
GCrs1491710 AA+AC 187/470 Ref Ref 
  CC 0/0 - - 
GCrs1873590 AA+AG 186/470 Ref Ref 
  GG 0/0 - - 
GCrs2282679 AA+AC 169/434 Ref Ref 
  CC 18/35 1.27 (0.69, 2.34) 0.44 
GCrs3733359 AG+GG 186/468 Ref Ref 
  AA 1/2 1.55 (0.14, 17.5) 0.72 
GCrs3755967 AG+GG 169/435 Ref Ref 
  AA 18/35 1.28 (0.70, 2.35) 0.43 
GCrs3775152 AA+AC       
  CC       
GCrs4364228 AA+AG 186/468 Ref Ref 
  GG 1/2 1.17 (0.10, 13.4) 0.90 
GCrs6817912  AG+GG 186/468 Ref Ref 
  AA 1/2 1.55 (0.14, 17.5) 0.72 
GCrs10488854 AG+GG 187/470 Ref Ref 
  AA 0/0 - - 








  GG 0/0 - - 
GCrs16847015 AC+CC 187/468 Ref Ref 
  AA 0/2 <0.001 (<0.001, >999.999) 0.98 
GCrs16847019 AG+GG 187/470 Ref Ref 
  AA 0/0 - - 
GCrs16847024 AG+GG 187/470 Ref Ref 
  AA 0/0 - - 
GCrs373749 AG+GG       
  AA       
GCrs16847028 AG+GG 182/464 Ref Ref 
  AA 5/6 1.82 (0.53, 6.26) 0.34 
GCrs17467825 AA+AG 169/426 Ref Ref 
  GG 18/35 1.25 (0.68, 2.30) 0.48 








Table 4.10 Recessive Model - Genotype frequencies by 25(OH)D cut-point and association between SNPs and 
vitamin D status among African Americans 
 
Gene + SNP rs# Genotype African American (N = 524)  below/above* 
25(OH)D 
Mean, SD  OR, 95% CI* P-value* 
GCrs4588 AC+CC 204/302 17.6 (7.39) Ref Ref 
  AA 7/5 15.3 (7.96) 2.38 (0.73, 7.80) 0.15 
GCrs7041 AA+AC 204/299 17.6 (7.39) Ref Ref 
  CC 9/12 17.3 (7.18) 1.34 (0.54, 3.35) 0.53 
GCrs188812 AA+AT 208/302 17.6 (7.39) Ref Ref 
  TT 5/9 16.4 (7.02) 0.82 (0.27, 2.49) 0.72 
GCrs222016 AG+GG 167/230 17.4 (7.60) Ref Ref 
  AA 46/81 17.9 (6.64) 0.84 (0.55, 1.27) 0.40 
GCrs222023 AG+GG 165/241 17.5 (7.30) Ref Ref 
  AA 41/63 17.6 (7.48) 0.88 (0.56, 1.37) 0.57 
GCrs222040 AG+GG 180/158 17.3 (7.24) Ref Ref 
  AA 32/53 18.9 (7.92) 0.89 (0.55, 1.45) 0.64 
GCrs222049 CC+CG 211/301 17.5 (7.38) Ref Ref 
  GG 2/10 21.3 (6.58) 0.27 (0.06, 1.27) 0.10 
GCrs222054 CC+CG 209/295 17.5 (7.37) Ref Ref 
  GG 4/16 19.3 (7.44) 0.33 (0.11, 0.998) 0.05 
GCrs705117 AG+GG 189/283 17.6 (7.46) Ref Ref 
  AA 24/28 17.0 (6.54) 1.53 (0.84, 2.80) 0.16 
GCrs705119 AA+AC 206/301 17.5 (7.40) Ref Ref 
  CC 7/10 18.2 (6.58) 1.31 (0.47, 3.71) 0.61 








  AA 52/78 17.6 (7.21) 0.93 (0.62, 1.40) 0.72 
GCrs705124  AG+GG 201/286 17.5 (7.40) Ref Ref 
  AA 12/25 18.1 (7.16) 0.65 (0.32, 1.33) 0.24 
GCrs705125 AC+CC 173/245 17.5 (7.64) Ref Ref 
  AA 39/66 17.7 (6.26) 0.90 (0.57, 1.41) 0.64 
GCrs1352845 AA+AG 176/276 17.7 (7.35) Ref Ref 
  GG 37/35 16.4 (7.74) 1.59 (0.96, 2.64) 0.07 
GCrs1491710 AA+AC 174/267 17.8 (7.24) Ref Ref 
  CC 39/40 15.9 (7.85) 1.43 (0.88, 2.32) 0.15 
GCrs1873590 AA+AG 208/310 17.6 (7.36) Ref Ref 
  GG 5/1 9.92 (4.33) 7.43 (0.85, 64.7) 0.07 
GCrs2282679 AA+AC 208/306 17.6 (7.36) Ref Ref 
  CC 5/5 16.0 (8.24) 1.73 (0.48, 6.15) 0.40 
GCrs3733359 AG+GG 195/289 17.6 (7.31) Ref Ref 
  AA 17/22 16.7 (7.99) 1.08 (0.56, 2.10) 0.82 
GCrs3755967 AG+GG 208/306 17.6 (7.36) Ref Ref 
  AA 5/5 16.0 (8.24) 1.73 (0.48, 6.15) 0.40 
GCrs3775152 AC+CC 190/282 17.6 (7.36) Ref Ref 
  AA 23/29 17.1 (7.56) 1.14 (0.63, 2.03) 0.67 
GCrs4364228 AA+AG 179/259 17.4 (7.23) Ref Ref 
  GG 34/51 18.4 (8.02) 0.92 (0.57, 1.49) 0.74 
GCrs6817912  AG+GG 209/309 17.5 (7.29) Ref Ref 
  AA 4/2 18.4 (14.12) 2.68 (0.48, 14.9) 0.26 
GCrs10488854 AG+GG 208/308 17.6 (7.40) Ref Ref 
  AA 5/3 15.01 (5.67) 2.35 (0.55, 10.0) 0.25 








  GG 12/14 17.7 (8.69) 1.19 (0.53, 2.64) 0.67 
GCrs16847015 AC+CC 204/306 17.6 (7.31) Ref Ref 
  AA 9/5 15.7 (9.61) 2.43 (0.80, 7.40) 0.12 
GCrs16847019 AG+GG 211/308 17.5 (7.32) Ref Ref 
  AA 2/3 22.4 (11.9) 1.02 (0.17, 6.17) 0.99 
GCrs16847024 AG+GG 210/307 17.6 (7.35) Ref Ref 
  AA 3/4 15.4 (9.16) 1.09 (0.24, 4.99) 0.91 
GCrs373749 AG+GG 205/303 17.6 (7.38) Ref Ref 
  AA 7/8 16.4 (6.70) 1.25 (0.44, 3.51) 0.68 
GCrs16847028 AG+GG 209/308 17.6 (7.39) Ref Ref 
  AA 4/3 14.6 (5.94) 1.63 (0.36, 7.40) 0.53 
GCrs17467825 AA+AG 204/301 17.6 (7.36) Ref Ref 
  GG 5/4 14.7 (7.47) 2.24 (0.58, 8.63) 0.24 
* <15ng/ml = below 








Table 4.11Recessive Model - Genotype frequencies by 25(OH)D cut-point and association between SNPs and 
vitamin D status among European Americans 
 
Gene + SNP rs# Genotype European American (N = 657) below/above* 
25(OH)D 
Mean, SD OR, 95% CI P-value 
GCrs4588 AC+CC 159/442 25.0 (9.81) Ref Ref 
  AA 26/26 21.2 (7.06) 2.80 (1.58, 4.97) 0.0004 
GCrs7041 AC+CC 137/395 25.2 (10.0) Ref Ref 
  AA 51/73 22.2 (7.35) 2.02 (1.35, 3.04) 0.0007 
GCrs188812 AA+AT 185/461 24.6 (9.70) Ref Ref 
  TT 3/8 25.9 (6.40) 0.94 (0.25, 3.58) 0.92 
GCrs222016 AA+AG 184/460 24.6 (9.71) Ref Ref 
  GG 4/9 25.7 (6.57) 1.12 (0.934, 3.68) 0.86 
GCrs222023 AG+GG 185/454 24.6 (9.66) Ref Ref 
  AA 1/1 25.0 (10.3) 2.47 (0.15, 39.8) 0.52 
GCrs222040 AA+AG 138/397 25.2 (10.0) Ref Ref 
  GG 50/71 22.2 (7.41) 2.04 (1.35, 3.08) 0.0007 
GCrs222049 CC+CG 188/468 24.7 (9.66) Ref Ref 
 GG 0/1 29.6 (-) <0.001 (<0.001, >999.999) 0.98 
GCrs222054 CC+CG 178/427 24.5 (9.78) Ref Ref 
  GG 10/42 26.9 (7.73) 0.57 (0.28, 1.17) 0.13 
GCrs705117 AA+AG 186/460 24.6 (9.68) Ref Ref 
  GG 2/9 27.9 (7.62) 0.55 (0.12, 2.58) 0.45 
GCrs705119 AC+CC 140/404 25.2 (9.96) Ref Ref 
  AA 48/65 22.0 (7.51) 2.15 (1.41, 3.27) 0.0004 








  AA 47/65 22.0 (7.53) 2.08 (1.36, 3.18) 0.0007 
GCrs705124  AG+GG 182/458 24.7 (9.71) Ref Ref 
  AA 5/9 24.0 (7.17) 1.40 (0.46, 4.26) 0.55 
GCrs705125 AA+AC 180/454 24.6 (9.66) Ref Ref 
  CC 8/13 25.8 (9.67) 1.56 (0.63, 3.83) 0.33 
GCrs1352845 AA+AG 180/458 24.7 (9.68) Ref Ref 
  GG 8/10 24.3 (8.94) 2.05 (0.79, 5.30) 0.14 
GCrs1491710 AA+AC 188/469 24.7 (9.65) Ref Ref 
  CC - - - - 
GCrs1873590 AA+AG 188/468 24.7 (9.66) Ref Ref 
  GG - - - - 
GCrs2282679 AA+AC 162/441 25.0 (9.81) Ref Ref 
  CC 26/27 21.3 (7.07) 2.64 (1.49, 4.66) 0.0008 
GCrs3733359 AG+GG 186/468 24.7 (9.66) Ref Ref 
  AA 2/1 22.8 (8.24) 5.08 (0.46, 56.4) 0.19 
GCrs3755967 AG+GG 162/442 25.0 (9.80) Ref Ref 
  AA 26/27 21.3 (7.07) 2.65 (1.50, 4.67) 0.0008 
GCrs3775152 AA+AC         
  CC         
GCrs4364228 AA+AG 187/467 24.7 (9.67) Ref Ref 
  GG 1/2 23.7 (5.19) 1.25 (0.11, 13.9) 0.85 
GCrs6817912  AG+GG 186/468 24.7 (9.66) Ref Ref 
  AA 2/1 22.8 (8.24) 5.08 (0.46, 56.4) 0.19 
GCrs10488854 AG+GG 188/469 24.7 (9.65) Ref Ref 
  AA - - - - 








  GG - - - - 
GCrs16847015 AC+CC 187/468 24.6 (9.84) Ref Ref 
  AA 1/1 25.0 (10.3) 2.53 (0.16, 40.7) 0.51 
GCrs16847019 AG+GG 188/469 24.7 (9.65) Ref Ref 
  AA - - - - 
GCrs16847024 AG+GG 188/469 24.7 (9.65) Ref Ref 
  AA - - - - 
GCrs373749 AG+GG         
  AA         
GCrs16847028 AG+GG 185/461 24.6 (9.66) Ref Ref 
  AA 3/8 27.6 (9.39) 0.93 (0.24, 3.57) 0.92 
GCrs17467825 AA+AG 160/435 24.9 (9.78) Ref Ref 
  GG 26/27 21.3 (7.07) 2.64 (1.49, 4.66) 0.0009 
* <20ng/ml = below 








Table 4.12 Dominant Model - Genotype frequencies and association between SNPs and aggressive prostate 
cancer among African Americans 
 
Gene + SNP rs# Genotype African American (N = 524) cases/control OR, 95% CI
* P-value* 
GCrs4588 CC 172/249 Ref Ref 
  AA+AC 44/53 1.18 (0.75, 1.85) 0.47 
GCrs7041 AA 143/208 Ref Ref 
  AC+CC 74/99 1.08 (0.74, 1.59) 0.68 
GCrs188812 AA 158/220 Ref Ref 
  AT+TT 59/87 1.06 (0.72, 1.57) 0.77 
GCrs222016 GG 50/92 Ref Ref 
  AA+AG 167/215 1.42 (0.94, 2.14) 0.09 
GCrs222023 GG 69/99 Ref Ref 
  AA+AG 143/199 1.02 (0.69, 1.50) 0.93 
GCrs222040 GG 78/101 Ref Ref 
  AG+AA 139/205 0.88 (0.61, 1.28) 0.50 
GCrs222049 CC 158/236 Ref Ref 
  CG+GG 59/71 1.23 (0.82, 1.84) 0.31 
GCrs222054 CC 156/179 Ref Ref 
  CG+GG 61/128 0.55 (0.38, 0.80) 0.0019 
GCrs705117 GG 105/165 Ref Ref 
  AA+AG 112/142 1.24 (0.86, 1.77) 0.25 
GCrs705119 AA 145/214 Ref Ref 








GCrs705120 CC 53/84 Ref Ref 
  AA+AC 160/219 1.16 (0.77, 1.73) 0.48 
GCrs705124 GG 127/171 Ref Ref 
  AA+AG 90/136 0.91 (0.64, 1.30) 0.60 
GCrs705125 CC 67/110 Ref Ref 
  AA+AC 150/196 1.27 (0.87, 1.86) 0.22 
GCrs1352845 AA 133/181 Ref Ref 
  AG+GG 84/126 0.89 (0.62, 1.28) 0.53 
GCrs1491710 AA 86/111 Ref Ref 
  AC+CC 128/195 0.82 (0.56, 1.18) 0.28 
GCrs1873590 AA 174/242 Ref Ref 
  AG+GG 43/65 0.93 (0.60, 1.44) 0.73 
GCrs2282679 AA 180/268 Ref Ref 
  AC+CC 37/39 1.36 (0.83, 2.23) 0.22 
GCrs3733359 GG 123/176 Ref Ref 
  AA+AG 94/130 1.03 (0.72, 1.47) 0.88 
GCrs3755967 GG 178/263 Ref Ref 
  AA+AG 39/44 1.29 (0.80, 2.08) 0.30 
GCrs3775152 CC 109/160 Ref Ref 
  AA+AC 108/147 1.08 (0.76, 1.54) 0.29 
GCrs4364228 AA 86/113 Ref Ref 
  AG+GG 130/194 0.87 (0.61, 1.25) 0.45 








  AA+AG 40/63 0.89 (0.57, 1.39) 0.61 
GCrs10488854 GG 164/242 Ref Ref 
  AA+AG 53/65 1.19 (0.79, 1.81) 0.41 
GCrs16846912 AA 138/177 Ref Ref 
  AG+GG 79/130 0.78 (0.54, 1.12) 0.17 
GCrs16847015 CC 162/207 Ref Ref 
  AA+AC 55/100 0.72 (0.49, 1.06) 0.23 
GCrs16847019 GG 166/237 Ref Ref 
  AA+AG 51/70 1.04 (0.68, 1.57) 0.87 
GCrs16847024 GG 182/269 Ref Ref 
  AA+AG 35/38 1.31 (0.79, 2.16) 0.29 
GCrs373749 GG 149/216 Ref Ref 
  AA+AG 68/90 1.08 (0.74, 1.59) 0.68 
GCrs16847028 GG 179/227 Ref Ref 
  AA+AG 38/80 0.61 (0.39, 0.94) 0.03 
GCrs17467825 AA 176/258 Ref Ref 
  AG+GG 38/42 1.31 (0.81, 2.13) 0.27 








Table 4.13 Dominant Model - Genotype frequencies and association between SNPs and aggressive prostate cancer 
among European Americans 
 
Gene + SNP rs# Genotype European American (N = 657) cases/control OR, 95% CI
* P-value* 
GCrs4588 CC 100/222 Ref Ref 
  AA+AC 86/236 0.80 (0.57, 1.14) 0.22 
GCrs7041 CC 58/138 Ref Ref 
  AA+AC 128/332 0.93 (0.64, 1.35) 0.69 
GCrs188812 AA 156/377 Ref Ref 
  AT+TT 31/93 0.82 (0.52, 1.29) 0.39 
GCrs222016 AA 140/328 Ref Ref 
  AG+GG 47/142 0.77 (0.52, 1.14) 0.19 
GCrs222023 GG 168/402 Ref Ref 
  AA+AG 16/55 0.66 (0.36, 1.21) 0.18 
GCrs222040 AA 60/141 Ref Ref 
  AG+GG 127/328 0.92 (0.63, 1.34) 0.67 
GCrs222049 CC 164/412 Ref Ref 
  CG+GG 23/58 1.01 (0.60, 1.70) 0.98 
GCrs222054 CC 100/235 Ref Ref 
  CG+GG 87/235 0.92 (0.65, 1.31) 0.66 
GCrs705117 AA 138/335 Ref Ref 
  AG+GG 49/135 0.89 (0.60, 1.32) 0.57 
GCrs705119 CC 61/147 Ref Ref 








GCrs705120 CC 63/151 Ref Ref 
  AA+AC 124/318 0.97 (0.67, 1.40) 0.86 
GCrs705124  GG 155/377 Ref Ref 
  AA+AG 32/90 0.89 (0.56, 1.40) 0.60 
GCrs705125 AA 136/302 Ref Ref 
  AC+CC 51/166 0.68 (0.47, 1.00) 0.05 
GCrs1352845 AA 163/392 Ref Ref 
  AG+GG 23/78 0.67 (0.40, 1.13) 0.13 
GCrs1491710 AA 185/462 Ref Ref 
  AC+CC 8-Feb 0.51 (0.10, 2.72) 0.43 
GCrs1873590 AA 186/467 Ref Ref 




GCrs2282679 AA 101/231 Ref Ref 
  AC+CC 86/238 0.85 (0.60, 1.21) 0.37 
GCrs3733359 GG 171/405 Ref Ref 
  AA+AG 16/65 0.56 (0.31, 1.01) 0.05 
GCrs3755967 GG 100/222 Ref Ref 
  AA+AG 87/248 0.81 (0.57, 1.14) 0.22 
GCrs3775152 AA       
  AC+CC       
GCrs4364228 AA 162/405 Ref Ref 
  AG+GG 25/65 0.95 (0.57, 1.58) 0.85 








  AA+AG 15/68 0.51 (0.28, 0.93) 0.03 
GCrs10488854 GG 185/465 Ref Ref 
  AA+AG 5-Feb 0.70 (0.12, 4.21) 0.70 
GCrs16846912 AA 187/467 Ref Ref 




GCrs16847015 CC 172/423 Ref Ref 
  AA+AC 15/47 0.77 (0.41, 1.42) 0.40 
GCrs16847019 GG 187/464 Ref Ref 




GCrs16847024 GG 185/467 Ref Ref 
  AA+AG 3-Feb 1.07 (0.16, 7.10) 0.95 
GCrs373749 GG       
  AA+AG       
GCrs16847028 GG 155/372 Ref Ref 
  AA+AG 32/98 0.79 (0.50, 1.23) 0.30 
GCrs17467825 AA 100/218 Ref Ref 
  AG+GG 87/243 0.81 (0.57, 1.14) 0.23 








Table 4.14 Dominant Model - Genotype frequencies by 25(OH)D cut-point and association between SNPs and vitamin 
D status among African Americans 
 
Gene + SNP rs# Genotype 
African American (N = 524) 25(OH)D 
OR, 95% CI** P-value** 
below/above* Mean, SD 
GCrs4588 CC 163/258 17.8 (7.54)  Ref Ref 
  AA+AC 48/49 16.4 (6.72) 1.66 (1.06, 2.61) 0.03 
GCrs7041 AA 150/201 17.2 (7.36) Ref Ref 
  AC+CC 63/100 18.3 (7.37) 0.83 (0.57, 1.22) 0.35 
GCrs188812 AA 152/226 17.8 (7.50) Ref Ref 
  AT+TT 61/85 16.9 (7.03) 1.048 (0.71, 1.55) 0.81 
GCrs222016 GG 54/88 17.6 (7.42) Ref Ref 
  AA+AG 159/223 17.5 (7.37) 1.27 (0.85, 1.91) 0.24 
GCrs222023 GG 62/106 17.6 (6.45) Ref Ref 
  AA+AG 144/198 17.5 (7.73) 1.17 (0.79, 1.73) 0.43 
GCrs222040 GG 74/105 17.4 (7.52) Ref Ref 
  AG+AA 138/206 17.6 (7.31) 0.99 (0.68, 1.44) 0.96 
GCrs222049 CC 165/229 17.4 (7.47) Ref Ref 
  CG+GG 48/82 18.0 (7.07) 0.79 (0.53, 1.20) 0.27 
GCrs222054 CC 148/187 17.1 (7.58) Ref Ref 
  CG+GG 65/124 18.3 (6.96) 0.66 (0.45, 0.96) 0.03 
GCrs705117 GG 110/160 17.4 (7.54) Ref Ref 
  AA+AG 103/151 17.7 (7.21) 1.10 (0.77, 1.58) 0.61 








  AC+CC 60/105 18.0 (6.95) 0.83 (0.56, 1.23) 0.34 
GCrs705120 CC 57/80 17.6 (7.54) Ref Ref 
  AA+AC 152/227 17.5 (7.25) 0.93 (0.62, 1.39) 0.72 
GCrs705124  GG 128/170 17.5 (7.51) Ref Ref 
  AA+AG 85/141 17.7 (7.21) 0.78 (0.54, 1.11) 0.16 
GCrs705125 CC 74/103 17.6 (7.98)  Ref Ref 
  AA+AC 138/208 17.5 (7.06) 1.00 (0.69, 1.47) 0.99 
GCrs1352845 AA 129/185 17.3 (7.02) Ref Ref 
  AG+GG 84/126 17.8 (7.88) 0.92 (0.64, 1.33) 0.67 
GCrs1491710 AA 73/124 18.1 (7.36) Ref Ref 
  AC+CC 140/183 17.1 (7.34) 1.26 (0.87, 1.83) 0.22 
GCrs1873590 AA 164/252 17.8 (7.41) Ref Ref 
  AG+GG 49/59 16.6 (7.15) 1.20 (0.78, 1.85) 0.41 
GCrs2282679 AA 174/274 17.8 (7.50) Ref Ref 
  AC+CC 39/37 16.1 (6.44) 1.86 (1.13, 3.06) 0.02 
GCrs3733359 GG 125/174 17.3 (6.99) Ref Ref 
  AA+AG 87/137 17.9 (7.84) 0.85 (0.60, 1.22) 0.39 
GCrs3755967 GG 170/271 17.8 (7.46) Ref Ref 
  AA+AG 43/40 16.2 (6.78) 1.88 (1.16, 3.05) 0.01 
GCrs3775152 CC 99/170 18.2 (7.22) Ref Ref 
  AA+AC 114/141 16.9 (7.50) 1.32 (0.92, 1.88) 0.13 








  AG+GG 132/192 17.5 (7.35) 0.96 (0.67, 1.39) 0.83 
GCrs6817912  GG 173/248 17.4 (7.24) Ref Ref 
  AA+AG 40/63 18.2 (7.92) 0.88 (0.56, 1.37) 0.57 
GCrs10488854 GG 162/244 17.8 (7.47) Ref Ref 
  AA+AG 51/67 16.8 (7.02) 1.11 (0.73, 1.69) 0.63 
GCrs16846912 AA 124/191 17.6 (7.22) Ref Ref 
  AG+GG 89/120 17.5 (7.62) 1.11 (0.78, 1.59) 0.57 
GCrs16847015 CC 148/221 17.4 (7.04) Ref Ref 
  AA+AC 65/90 17.8 (8.14) 1.02 (0.70, 1.50) 0.91 
GCrs16847019 GG 168/235 17.6 (7.36) Ref Ref 
  AA+AG 45/76 17.5 (7.44) 0.78 (0.51, 1.19) 0.25 
GCrs16847024 GG 181/270 17.6 (7.32) Ref Ref 
  AA+AG 32/41 16.9 (7.73) 1.17 (0.71, 1.94) 0.54 
GCrs373749 GG 147/218 17.6 (7.36) Ref Ref 
  AA+AG 65/93 17.5 (7.40) 1.00 (0.68, 1.47) 0.99 
GCrs16847028 GG 160/246 17.6 (7.27) Ref Ref 
  AA+AG 53/65 17.2 (7.75) 1.25 (0.82, 1.90) 0.29 
GCrs17467825 AA 166/268 17.8 (7.43) Ref Ref 
  AG+GG 43/37 16.0 (6.85) 2.05 (1.26, 3.36) 0.0041 
* <15ng/ml = below 








Table 4.15 Dominant Model - Genotype frequencies by 25(OH)D cut-point and association between SNPs and vitamin D 
status among European Americans 
 
Gene + SNP rs# Genotype European American (N = 657)  below*/above 
25(OH)D 
 Mean, SD OR, 95% CI
** P-value** 
GCrs4588 CC 68/254 26.7 (11.5) Ref Ref 
  AA+AC 117/214 22.7 (6.97) 2.05 (1.45, 2.91) <.0001 
GCrs7041 CC 41/155 27.3 (13.5) Ref Ref 
  AA+AC 147/313 23.5 (7.15) 1.78 (1.19, 2.64) 0.0046 
GCrs188812 AA 148/385 24.8 (9.96) Ref Ref 
  AT+TT 40/84 24.1 (8.24) 1.25 (0.82, 1.90) 0.31 
GCrs222016 AA 134/334 24.6 (10.21) Ref Ref 
  AG+GG 54/135 24.8 (8.12) 0.995 (0.69, 1.45) 0.98 
GCrs222023 GG 168/402 24.45 (9.84) Ref Ref 
  AA+AG 18/53 25.5 (8.07) 0.81 (0.46, 1.42) 0.46 
GCrs222040 AA 44/157 27.2 (13.4) Ref Ref 
  AG+GG 144/311 23.5 (7.17) 1.65 (1.12, 2.44) 0.01 
GCrs222049 CC 167/409 24.7 (9.96) Ref Ref 
  CG+GG 21/60 24.5 (7.20) 0.86 (0.51, 1.46) 0.57 
GCrs222054 CC 101/234 24.2 (8.27) Ref Ref 
  CG+GG 87/235 25.2 (10.9) 0.86 (0.61, 1.21) 0.38 
GCrs705117 AA 139/334 24.7 (10.4) Ref Ref 
  AG+GG 49/135 24.5 (7.42) 0.87 (0.59, 1.28) 0.47 








  AA+AC 141/308 23.6 (7.19) 1.57 (1.07, 2.30) 0.02 
GCrs705120 CC 49/165 26.8 (13.1) Ref Ref 
  AA+AC 139/303 23.6 (7.20) 1.55 (1.06, 2.26) 0.02 
GCrs705124  GG 150/382 24.8 (9.99) Ref Ref 
  AA+AG 37/85 24.3 (8.10) 1.11 (0.72, 1.71) 0.62 
GCrs705125 AA 124/314 24.8 (10.5) Ref Ref 
  AC+CC 64/153 24.4 (7.83) 1.06 (0.74, 1.52) 0.76 
GCrs1352845 AA 163/392 24.5 (9.93) Ref Ref 
  AG+GG 25/76 25.6 (7.99) 0.79 (0.48, 1.28) 0.33 
GCrs1491710 AA 183/464 24.7 (9.68) Ref Ref 
  AC+CC 5-May 19.8 (6.41) 2.59 (0.71, 9.51) 0.15 
GCrs1873590 AA 185/468 24.7 (9.65) Ref Ref 




GCrs2282679 AA 73/259 26.4 (11.4) Ref Ref 
  AC+CC 115/209 22.8 (6.98) 1.96 (1.39, 2.77) 0.0001 
GCrs3733359 GG 168/408 24.6 (9.92) Ref Ref 
  AA+AG 20/61 25.0 (7.49) 0.79 (0.46, 1.35) 0.39 
GCrs3755967 GG 69/253 26.7 (11.5) Ref Ref 
  AA+AG 119/216 22.7 (6.96) 2.03 (1.43, 2.87) <.0001 
GCrs3775152 AA         
  AC+CC         








  AG+GG 26/64 24.5 (7.27) 1.02 (0.62, 1.66) 0.95 
GCrs6817912  GG 166/408 24.6 (9.93) Ref Ref 
  AA+AG 22/61 24.9 (7.48) 0.89 (0.53, 1.49) 0.65 
GCrs10488854 GG 185/465 24.7 (9.67) Ref Ref 
  AA+AG 4-Mar 19.7 (7.06) 1.88 (0.38, 9.35) 0.44 
GCrs16846912 AA 186/468 24.67 (9.67) Ref Ref 
  AG+GG 1-Feb 20.2 (5.92) 5.16 (0.46, 57.5) 0.18 
GCrs16847015 CC 173/422 24.5 (9.84) Ref Ref 
  AA+AC 15/47 25.7 (7.61) 0.77 (0.42, 1.42) 0.41 
GCrs16847019 GG 186/465 24.7 (9.64) Ref Ref 
  AA+AG 4-Feb 24.9 (12.1) 1.24 (0.23, 6.85) 0.80 
GCrs16847024 GG 188/464 24.7 (9.69) Ref Ref 




GCrs373749 GG         
  AA+AG         
GCrs16847028 GG 146/381 24.9 (10.1) Ref Ref 
  AA+AG 42/88 23.7 (7.58) 1.25 (0.83, 1.89) 0.29 
GCrs17467825 AA 69/249 26.6 (11.5) Ref Ref 
  AG+GG 117/213 22.8 (6.92) 1.99 (1.40, 2.82) 0.0001 
* <20ng/ml = below 








Table 4.16 Polygenic risk score –Association between polygenic risk score and aggressive prostate cancer and vitamin D 
status   
Aggressiveness  
(n) 







































(95%CI)e   
AAa 0 38 40 15.8 
(6.59) 
1.0 (ref)  1.0 (ref) 
1.85 (0.75, 
4.56) 









 1.0 (ref) 
1.52 (0.92, 
2.49) 
 0.99 (0.46, 
2.11) 
0.74 (0.36, 
1.53)   





 1.0 (ref) 
1.94 (0.93, 
4.07) 
 0.48 (0.20, 
1.17) 
0.47 (0.22, 
1.01)   
                          
EAb 0 87 248 22.7 
(6.95) 
1.0 (ref)  1.0 (ref) 
0.80 (0.47, 
1.45) 









 1.0 (ref) 
0.71 (0.28, 
1.79) 
 1.36 (0.55, 
3.38) 
1.41 (0.82, 
2.41)   





 1.0 (ref) 
0.96 (0.44, 
2.07) 
 1.08 (0.48, 
2.43) 
1.25 (0.78, 
2.01)   
                          
aBlack: rs4588 and rs222054 
bWhite: rs4588 and rs7041 
c association between polygenic risk score and prostate cancer aggressiveness; adjusted for age and ancestry 
d association between 25(OH)D and prostate cancer aggressiveness stratified by polygenic risk score; adjusted for age and ancestry 
e association between polygenic risk score and prostate cancer aggressiveness stratified by 25(OH)D; adjusted for age and ancestry 








Table 4.17 Model summaries for SNPs by prostate cancer aggressiveness and 25(OH)D among African Americans  
GC SNPs Aggressive PCa
a 25(OH)Db 
Additive Recessive Dominant Additive Recessive Dominant 
rs4588 1.21 (0.68, 2.16) 1.39 (0.44, 4.44) 1.18 (0.75, 1.85) 1.64 (0.90, 2.98) 2.38 (0.73, 7.80) 1.66 (1.06, 2.61) 
rs222054 0.63 (0.45, 0.87) 0.84 (0.33, 2.16) 0.55 (0.38, 0.80) 0.65 (0.47, 0.90) 0.33 (0.11, 0.998) 0.66 (0.45, 0.96) 
rs16847015 0.69 (0.49, 0.98) 0.24 (0.05, 1.07) 0.72 (0.49, 1.06) 1.11 (0.79, 1.55) 2.43 (0.80, 7.40) 1.02 (0.70, 1.50) 
rs16847028 0.64 (0.43, 0.96) 0.64 (0.12, 3.37) 0.61 (0.39, 0.94) 1.24 (0.85, 1.82) 1.63 (0.36, 7.40) 1.25 (0.82, 1.90) 
rs2282679 1.22 (0.81, 1.85) 0.84 (0.23, 3.04) 1.36 (0.83, 2.23) 1.65 (1.08, 2.51) 1.73 (0.48, 6.15) 1.86 (1.13, 3.06) 
rs3755967 1.18 (0.79, 1.77) 0.84 (0.23, 3.04) 1.29 (0.80, 2.08) 1.67 (1.11, 2.53) 1.73 (0.48, 6.15) 1.88 (1.16, 3.05) 
rs17467825 1.16 (0.77, 1.77) 0.60 (0.15, 2.45) 1.31 (0.81, 2.13) 1.85 (1.21, 2.83) 2.24 (0.58, 8.63) 2.05 (1.26, 3.36) 
a OR for high aggressive PCa           








Table 4.18 Model summaries for SNPs by prostate cancer aggressiveness and 25(OH)D among European Americans 
GC SNPs Aggressive PCa
a 25(OH)Db 
Additive Recessive Dominant Additive Recessive Dominant 
rs4588 0.90 (0.69, 1.19) 1.19 (0.64, 2.21) 0.80 (0.57, 1.14) 1.89 (1.45, 2.48) 2.80 (1.58, 4.97) 2.05 (1.45, 2.91) 
rs7041 0.84 (0.65, 1.08) 0.63 (0.39, 1.02) 0.93 (0.64, 1.35) 1.63 (1.27, 2.09) 2.02 (1.35, 3.04) 1.78 (1.19, 2.64) 
rs705119 0.89 (0.69, 1.14) 0.69 (0.43, 1.13) 0.96 (0.67, 1.40) 1.57 (1.22, 2.02) 2.15 (1.41, 3.27) 1.57 (1.07, 2.30) 
rs705120 0.89 (0.69, 1.15) 0.70 (0.43, 1.15) 0.97 (0.67, 1.40) 1.55 (1.20, 1.98) 2.08 (1.36, 3.18) 1.55 (1.06, 2.26) 
rs222040 0.85 (0.66, 1.10) 0.66 (0.41, 1.07) 0.92 (0.63, 1.34) 1.58 (1.23, 2.03) 2.04 (1.35, 3.08) 1.65 (1.12, 2.44) 
rs2282679 0.95 (0.72, 1.25) 1.27 (0.69, 2.34) 0.85 (0.60, 1.21) 1.81 (1.39, 2.36) 2.64 (1.49, 4.66) 1.96 (1.39, 2.77) 
rs3755967 0.92 (0.70, 1.21) 1.28 (0.70, 2.35) 0.81 (0.57, 1.14) 1.86 (1.42, 2.43) 2.65 (1.50, 4.67) 2.03 (1.43, 2.87) 
rs17467825 0.92 (0.70, 1.20) 1.25 (0.68, 2.30) 0.81 (0.57, 1.14) 1.83 (1.41, 2.40) 2.64 (1.49, 4.66) 1.99 (1.40, 2.82) 
rs6817912 0.55 (0.31 0.98) 1.55 (0.14, 17.5) 0.51 (0.28, 0.93) 0.96 (0.59, 1.57) 5.08 (0.46, 56.4) 0.89 (0.53, 1.49) 
a OR for high aggressive PCa           









In this study, the relationship between GC SNPs, prostate cancer aggressiveness 
and levels of vitamin D were examined. This was accomplished by using genetic models 
to assess the differing risks with varied genotypes and the creation of combined 
genotypes (GCrs7041 and GCrs4588) and polygenic risk scores.  
When assessing the relationship between combined genotypes of GCrs7041 and 
GCrs4588, a similar model was used as described in the Abbas et al. study which 
examined these genotypes in relation to breast cancer.46 In the current study individuals 
with the Gc2-2 genotype had the lowest concentration of 25(OH)D of all combined 
genotypes in both races, consistent with the results from other studies.33,46 The Abbas et 
al. study used the most frequent combined genotype as the referent group (Gc1s-1s), 
which was consistent with the referent group used among EAs in the current study, but 
not among AAs where Gc1f-1f was the most frequent combined genotype. When 
examining the relationship with aggressive prostate cancer, only the Gc2-1f combined 
genotype was associated with a statistically significant decreased risk of high aggressive 
prostate cancer among EAs. No other associations were statistically significant in either 
race. Not many studies have studied the relationship of these combined genotypes in 
relation to prostate cancer but results from a study by Maneechay et al. showed that Gc2-
1f significantly decreased risk for lung cancer. 35  






cancer across all three models (Table 4.17 and 4.18), only four SNPs were statistically 
significant (rs6817912, rs222054, rs16847028 and rs16847015). In both the additive and 
dominant models for AAs, the GCrs222054 and GCrs16847028 SNPs were significantly 
associated with decreased risk of aggressive prostate cancer. These results suggest that 
having at least one copy of the ‘G’ allele in GCrs222054 and at least one copy of ‘A’ in 
GCrs16847028, reduces the risk of high aggressive prostate cancer in AAs. 
GCrs6817912 had the same effect on aggressiveness but only among EAs, suggesting 
that EAs with at least one copy of the ‘A’ allele in this SNP have a decreased risk of high 
aggressive prostate cancer. There was no evidence of an association between SNPs and 
prostate cancer aggressiveness in the recessive model, likely due to reduced power in the 
recessive model analyses given the smaller number of subjects who were homozygous 
variant for the minor allele for each of the SNPs.  
  Our study found a slight suggestion of a decreased risk (Table 4.9 p-value = 
0.058) of high aggressive prostate cancer in the recessive model for the GCrs7041 SNP 
among EAs, implying the presence of a protective association occurring among 
individuals who were homozygous for the ‘A’ allele in GCrs7041. This contradicts the 
findings in the study by Gilbert et al., where GCrs7041-T (labeled as GCrs7041-A in our 
study) significantly increased the risk of prostate cancer.20 Additionally, our study looked 
at the effect for each additional copy of the ‘A’ allele in rs7041 (Table 4.5) among EAs 
and found no significant association. Other studies have examined GCrs7041 in relation 
to overall or advanced prostate cancer and found no significant associations.19,39 This 
current study stratified the GC SNPs by race and examined associations with high 
aggressive prostate cancer, which could partially explain why the results differed from 






free controls were the comparison.20  
 Evidence of associations between GC SNPs and low levels of 25(OH)D were 
found in nine SNPs (rs4588, rs7041, rs222040, rs705119, rs705120, rs2282679, 
rs3755967, rs17467825 and rs222054) across all three models (Tables 4.17 and 4.18), 
which are consistent with the findings of other studies.19,21,35 Eight of these SNPs 
significantly increased the risk of having low levels of 25(OH)D among EAs only 
(rs4588, rs7041, rs222040, rs705119, rs705120, rs2282679, rs3755967 and 
rs17467825), while among AAs, only three of the SNPs increased the risk for the 
dominant and additive models (rs2282679, rs3755967and rs17467825), and one SNP 
was associated with increased risk of having low 25(OH)D for the dominant model only 
(rs4588). Also, among AAs, the rs222054 SNP was associated with lower odds of having 
low 25(OH)D across all three genetic models (Table 4.17). Our findings are consistent 
with the results for others studies indicating that GCrs2282679 and GCrs7041 are 
associated with differences in 25(OH)D levels.19,20  Specifically, our results were 
consistent with other studies which indicated that rs7041-A in EAs and  rs2282679-C in 
both races increased the risk of low levels of 25(OH)D.20  Additionally, our results were 
consistent with previous studies which indicated that the ‘A’ allele in GCrs4588 is 
associated with low levels of 25(OH)D among EAs.20,21,35 Results were similar for AAs, 
but only reached statistical significance for the dominant model of GCrs4588, and not the 
additive or recessive models. When comparing the mean levels of 25(OH)D of GCrs4588 
in the dominant model (Tables 4.14 and 4.15), the average level of 25(OH)D was greater 
in the ‘CC’ genotype compared to the ‘AA+AC’ genotype for both AAs and EAs, which 
was consistent with the findings from the Maneechay et al. study conducted in a Thai 






 In the current study, the polygenic risk score awarded a point to individuals 
carrying the genotype associated with the higher level of vitamin D based off the 
dominant model. Among AAs with a polygenic risk score of two (rs4588-CC and 
rs222054-CC) indicating higher 25(OH)D concentrations, the risk of high aggressive 
prostate cancer was decreased. However, in previous analyses of PCaP, AA men with 
higher 25(OH)D concentrations were found to have higher odds of high aggressive 
prostate cancer.18 Thus, it is not clear why a polygenic risk score indicating high 
25(OH)D would be associated with lower odds of high aggressive prostate cancer in this 
same population. Among both races, there were no significant findings when the model 
was stratified by score or the 2-level 25(OH)D, nor was there evidence of interaction 
between the polygenic risk score and 25(OH)D in relation to aggressive prostate cancer.  
Mean levels of plasma 25(OH)D were on average lower in AAs and a greater 
percentage were categorized as possessing what is considered to be low levels of vitamin 
D. These findings matched results from other studies which indicated that AAs have 
lower levels of vitamin D and/or insufficiency when compared to EAs. 7,15,17,21  
Strengths and Limitations 
 Some limitations in our study resulted from a relatively small sample size. While 
PCaP used a randomized recruitment procedure which allowed for a comparable 
enrollment rate for both races, the number of high aggressive cases and low aggressive 
“controls” enrolled were not equal. Due to the lack of genetic studies on AAs, the 
inclusion of approximately equal numbers of AAs and EAs in the study is an important 
strength. The generalizability of the study is limited to AA and EA men living in the 
Southern United States, though we would expect frequency of SNPs in vitamin D-related 






of prostate cancer was physician confirmed in addition to self-reported, and histological 
characteristics were also collected in order to distinguish between high aggressive and 
low aggressive cases. Although race was self-identified, ancestry was measured for all 
participants and was adjusted for in all models. All visits were completed within four 
months of diagnosis which provides information on characteristics of recently diagnosed 
individuals, but it restricts our ability to observe any changes occurring before diagnosis. 
For example, 25(OH)D was collected post-diagnosis, therefore we cannot determine 
whether circulating levels were consistent or changed before and after diagnosis. 
Significance and Recommendations 
Findings from our study suggest that more in-depth research needs to be 
conducted which further assesses the possible relationships between combined genotypes 
of GCrs7041 and GCrs4588 in relation to prostate cancer in both AAs and EAs. In the 
dominant model, levels of 25(OH)D were lower in both AAs and EAs in the rs4588 
‘AA+AC’ genotype, suggesting that the ‘A’ allele may increase the risk of low 25(OH)D. 
Our study only found evidence of risk increasing with the ‘A’ allele among EAs and not 
AAs. For rs7041, significant associations were only found for EAs and not AAs. There is 
contradicting literature on whether these SNPs are related to prostate cancer, but these 
differences may be explained by different populations being studied and effects of other 
unmeasured genetic variants. Some studies that have examined the relationship between 
the two SNPs and either overall or lethal prostate cancer risk reported no significant 
associations.19,39 In studies such as Gilbert et al. specific alleles in these SNPs were 
examined with prostate cancer risk and significant associations emerged.20 Our findings 
suggest that different alleles in GC SNPs may have varying effects on risk among AAs 






the additive, dominant and recessive models showed one SNP (rs222054) among AAs 
specifically to be associated with a decreased risk of high aggressive prostate cancer and 
increased risk of low levels of 25(OH)D which is a novel finding, not yet reported in 
previous studies among AAs. Findings from the polygenic risk score revealed evidence 
of risk of aggressive prostate cancer significantly decreasing among AAs possessing a 
score of two (rs4588-CC and rs222054-CC), indicating that these two specific SNP 
genotypes were related to higher levels of 25(OH)D and decreased risk of aggressive 
cancer. In conclusion, this study identified a novel polygenic risk score combining two 
SNPs GCrs4588 and GCrs222054 that appear to have an effect on levels vitamin D and 
prostate cancer aggressiveness among AAs. Future studies should specifically study these 
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